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ABSTRACT OF THE DISSERTATION 
DEVELOPMENT OF A SURFACE-ENHANCED RAMAN SPECTROSCOPY 
METHOD FOR THE DETECTION OF BENZODIAZEPINES IN URINE 
by 
Erika L. Doctor 
Florida International University, 2014 
Miami, Florida 
Professor Bruce McCord, Major Professor 
 Benzodiazepines are among the most prescribed compounds for anti-anxiety and 
are present in many toxicological screens.  These drugs are also prominent in the 
commission of drug facilitated sexual assaults due their effects on the central nervous 
system.  Due to their potency, a low dose of these compounds is often administered to 
victims; therefore, the target detection limit for these compounds in biological samples is 
10 ng/mL.  Currently these compounds are predominantly analyzed using immunoassay 
techniques; however more specific screening methods are needed. 
The goal of this dissertation was to develop a rapid, specific screening technique 
for benzodiazepines in urine samples utilizing surface-enhanced Raman spectroscopy 
(SERS), which has previously been shown be capable of to detect trace quantities of 
pharmaceutical compounds in aqueous solutions.  Surface enhanced Raman spectroscopy 
has the advantage of overcoming the low sensitivity and fluorescence effects seen with 
conventional Raman spectroscopy.  The spectra are obtained by applying an analyte onto 
a SERS-active metal substrate such as colloidal metal particles.  SERS signals can be 
viii 
   
further increased with the addition of aggregate solutions.  These agents cause the 
nanoparticles to amass and form hot-spots which increase the signal intensity.    
 In this work, the colloidal particles are spherical gold nanoparticles in aqueous 
solution with an average size of approximately 30 nm.  The optimum aggregating agent 
for the detection of benzodiazepines was determined to be 16.7 mM MgCl2,  providing 
the highest signal intensities at the lowest drug concentrations with limits of detection 
between 0.5 and 127 ng/mL.  A supported liquid extraction technique was utilized as a 
rapid clean extraction for benzodiazepines from urine at a pH of 5.0, allowing for clean 
extraction with limits of detection between 6 and 640 ng/mL.  It was shown that at this 
pH other drugs that are prevalent in urine samples can be removed providing the selective 
detection of the benzodiazepine of interest.   
 This technique has been shown to provide rapid (less than twenty minutes), 
sensitive, and specific detection of benzodiazepines at low concentrations in urine.  It 
provides the forensic community with a sensitive and specific screening technique for the 
detection of benzodiazepines in drug facilitated assault cases.    
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1. INTRODUCTION 
Benzodiazepines are commonly prescribed and easily accessible drugs in the 
United States which are often found during toxicological testing in cases of drug 
facilitated sexual assault (DFSA).  Many of the screening methods that are currently used 
are lengthy to perform, complicated, or do not successfully detect low concentrations of 
these types of drugs.  The goal of this dissertation was to develop a rapid screening 
technique for the detection of low concentration benzodiazepines in DFSA cases using 
surface enhanced Raman spectroscopy (SERS).  The use of Raman spectroscopy not only 
detects the drug, it also permits the determination of spectral information, highly useful in 
the presumptive identification of unknown compounds.  
1.1 Benzodiazepines 
1.1.1 Development and structure 
Benzodiazepines were first developed in the 1950s.  The discovery of these 
compounds caused a surge in the development of new compounds that would have 
superior pharmacological effects over existing tranquilizers, such as barbiturates.  The 
first benzodiazepine, chlordiazepoxide (Librium®), was unexpectedly synthesized by 
Sternbach in 1955 as a result of a ring extension of a quinazoline-3-N-oxide derivative.1  
The synthesis of homologues and analogs of this first compound was patented in 19592, 
and since then many structurally similar compounds have been created and marketed by 
drug companies for therapeutic uses as tranquilizers, hypnotics, and anxiolytics.3  As of 
the 2012 International Narcotic Control Board statistics, there were 35 benzodiazepines 
under international control, with alprazolam and diazepam being the most manufactured 
in the world as shown in Figure 1.4  
2 
   
 
Figure 1: Distribution of benzodiazepine manufacture in 2011 by type4 
 The structure of benzodiazepines are based on a 5-aryl-1,4-benzodiazpine 
backbone where the 6-7 bond of the 1,4-diazepine ring is fused to a benzene ring.  The 
aryl substituent at the 5 position is usually either a phenyl (diazepam) or 2’-halophenyl 
(flunitrazepam).  The main base structure constitutes the class of 1,4-benzodiazepines.3  
More recent benzodiazepines, developed in the 1980s, have an additional 1,3-diazole ring 
or 1,2,4-triazole linked to the 1-2 bond of the 1,4-diazepine ring, forming the class of 1,2-
imidazo and 1,2-triazolo-benzodiazepines, respectively (Figure 2, Table 1).3   The 
different substituents on the general structures change the duration of action and potency 
of the drug.  For example, the addition of an electron withdrawing group, such as a nitro 
group or a chlorine, on the benzene ring generally enhances activity.5  
3 
   
 
Figure 2: Base structures of (A) 1,4-benzodiazepines and (B) 1,2-triazolo- and 1,2-
imidazo benzodiazepines 6 
1,2- Triazolo- and 1,2-imidazo-benzodiazepines R1 X R4 R2’ R8 
Alprazolam -CH3 =N- -H -H -Cl 
Midazolam -CH3 =C- -H -F -Cl 
Triazolam -CH3 =N- -H -Cl -Cl 
1,4-Benzodiazepines R1 R2 R3 R2’ R8 
7-Amino-flunitrazepam (metabolite) -CH3 =O -H -F -NH2 
Chlordiazepoxide ----- -NHCH3 -H -H -Cl 
Clonazepam -H =O -H -Cl -NO2 
Diazepam -CH3 =O -H -H -Cl 
Flunitrazepam -CH3 =O -H -F -NO2 
Lorazepam -H =O -OH -Cl -Cl 
Nordiazepam (metabolite) -H =O -H -H -Cl 
Oxazepam (metabolite) -H =O -OH -H -Cl 
Table 1: R groups of benzodiazepines6  
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1.1.2 Pharmacology 
Benzodiazepines have a well-recognized mechanism of action.  These compounds 
act as central nervous system (CNS) depressants by binding to the receptors of one 
subtype of the neurotransmitter gama-amino butyric acid (GABA)A and inhibiting the 
release of GABA.  The GABAA  receptor is a ligand-gated ion channel that is activated 
by GABA.  The binding of benzodiazepines causes the inhibition of the release of GABA 
from the GABAA receptor resulting in the CNS depressant behavior of the drug by 
increasing the amount of ions transmitted through the channel (figure 3).87  
 
Figure 3:  GABAA receptor without benzodiazepine and with benzodiazepine, note that 
GABA and the benzodiazepines bind at a different site causing GABA to continually 
bind and increasing the flow of ions through the channel5, 87 
When the benzodiazepine binds to the receptor it induces a conformational 
change in the receptor.  This binding is separate to the binding pocket of the GABA 
agonist site.  Benzodiazepines promote the binding of the inhibitory neurotransmitter 
GABA to the GABAA receptors.  They do not directly activate the GABAA receptors but 
instead are positive allosteric modulators of the effects of GABA.87  The varied 
5 
   
pharmacological uses of the drugs are due to the multiple subtypes of GABAA receptors 
that involve benzodiazepines.5  The structure of the benzodiazepine has an effect on the 
onset of action and duration of action.  For the treatment of insomnia, hypnotic 
benzodiazepines are selected with a rapid onset but a longer duration of action than a 
benzodiazepine chosen to assist in anesthesia.5   
There are three main methods for the administration of benzodiazepines, 
intravenously, intramuscularly, and the most common, orally.  When taken orally, the 
drugs are completely absorbed by the body due to their high lipid solubility, but the rate 
of adsorption is dependent on the benzodiazepine.  The first-pass effect, which occurs 
when the drug is metabolized in the gastrointestinal tract before entering the bloodstream, 
is generally significant with benzodiazepines prior to distribution.5  Benzodiazepines 
have a range of elimination half-lives, and the administered compound can be classified 
based on this property.  Short-acting benzodiazepines, such as midazolam, have an 
elimination half-life less than 6 hours.  Benzodiazepines with an elimination half-life 
between 6-24 hours are intermediate-acting.  The group contains the majority of 
benzodiazepines including the most common, alprazolam.  Finally, long-acting 
benzodiazepines have an elimination half-life exceeding 24 hours.  This classification 
scheme does have complications due to the fact that many benzodiazepines produce 
active metabolites that may have a different elimination half-life than the parent drug.5, 7     
The metabolism of benzodiazepines occurs mainly in the liver.  Phase I 
metabolism of benzodiazepines follow four main routes: hydroxylation, deamination, 
reduction, and dealkylation, caused by the transformation of functional groups by the 
microsomal enzymes in the liver.5  Many of the major metabolites, such as nordiazepam 
6 
   
and oxazepam are pharmacologically active and as previously mentioned, have an effect 
on the activity of the benzodiazepine administered.  Metabolism pathways of a number of 
benzodiazepines are shown in Figures 4 and 5.  Phase II metabolism of benzodiazepines 
mainly involves the conjugation with glucuronic acid, producing the major urinary 
products.5   
 
Figure 4: Routes of metabolism for some 1,4-benzodiazepines3; 1-4 benzodiazepines can 
undergo dealkylation or deamination followed by hydroxylation and glucuronidation. 
7 
   
 
Figure 5: Routes of metabolism for 1,2-triazolo and 1,2-imidazo-benzodiazpines3; These 
groups of benzodiazepines can undergo ring cleavage or multiple hydroxylations 
followed by glucuronidation. 
1.1.3 Prevalence in Drug Facilitated Sexual Assaults 
Drug facilitated sexual assaults (DFSA) occur every day in the United States, with 
increasing frequency.  A DFSA is defined as “the voluntary or involuntary ingestion of a 
drug by a victim that results in an act of sexual activity without consent.”8  The 
impairment effects differ from one victim to another, however, there is incapacitation as a 
result of consuming a substance common to these types of cases.  Victims are often 
subjected not only to physical harm but also physiological harm, which is one of the main 
reasons these crimes are not reported immediately.8  The victim may not have any 
memory of the event, the person who committed the crime, or the circumstances 
surrounding the act.  They also may have feelings of shame, guilt, and embarrassment 
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and may not feel ready to report the crime to the authorities.8  The delay in reporting 
leads to reduced concentrations of drugs in body, thus, lowering the amount of drug 
present for an analyst to detect.  This adds to the challenge of detecting drugs in DFSA, 
which are already administered at low concentrations and have fast clearance rates.8 
Often victims are administered a drug unknowingly into food or beverages, in 
order for a criminal to incapacitate the victim.  While Rohypnol® (flunitrazepam) and 
gamma-hydroxybutyrate (GHB) are frequently mentioned in the media, a wide variety of 
compounds are used in the commission of such crimes.9,10,11,12  Criminals in these cases 
chose a drug that creates the desired physiological effects on a victim such as confusion, 
drowsiness, impaired judgment and memory, and loss of consciousness, among others.10  
Often the drugs chosen are central nervous system depressants, such as benzodiazepines, 
whose sedative effects can be enhanced in combination with ethanol.  As reported by the 
International Narcotic Control Board, benzodiazepines rank amongst the most widely and 
frequently prescribed medications in the world4, making them readily available for use in 
DFSA.9-12  Therefore, the ability to detect these compounds is critical to toxicologists 
today in order to determine the type of drug used in the cases of DFSA.  
Recommendations have been made for the detection limits required for analyzing urine 
specimens using standard analytical methods such as gas chromatography-mass 
spectrometry or liquid chromatography-mass chromatography.  The recommended 
maximum detection limit for one of the most common benzodiazepines, alprazolam is 10 
ng/mL and it was recommended that new techniques used for the determination of DFSA 
should meet this detection limit.11 
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1.2 Current Methods of Detection 
Screening techniques are used by toxicologist in order to determine the type of 
drugs present in a biological sample prior to confirmation of the quantity and identity of 
the drugs.  In terms of DFSA, the biological samples used are often urine, and many 
contain a vast variety of drugs, such as cocaine, nicotine, and other narcotics.8  This 
dissertation will discuss the screening techniques in terms of the detection of 
benzodiazepines and the complications that arise from their detection.  Benzodiazepines 
when used in DFSA cause a number of analytical problems for the toxicologist.  
Depending on the circumstances, the concentration of these drugs that are present in urine 
may very low.  This concentration is often less than 50 ng/mL due to a number of key 
factors.  These compounds are prescribed in low dosages, therefore the amount 
administered will be dictated by the dosage of the source pill.  Also many victims of 
these crimes do not report them immediately, allowing the drug to continue to be 
metabolized, reducing the amount present in urine.  The screening process is further 
complicated due to the metabolism process as described previously, which gives rise to 
multiple metabolites.13,14,15,9, 12, 16,17,18,19   
1.2.1 Immunoassay 
 Immunoassays are the screening tests most commonly utilized in toxicology 
laboratories.  They provide rapid screening at a low cost and are relatively accurate.5  
There are a number of types of tests which can be utilized such as enzymatic 
immunoassay15, enzyme multiplied immunoassay technique15,9,18,20, kinetic interaction of 
microparticle in solution20,19, and radioimmunoassay.19  Each of these tests involve 
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different enzymes and chemical reactions but all follow the same basic process.  All tests 
employ specific antibodies produced in the presence of the target drug or drug class, 
diazepam for most benzodiazepine assays, which will bind to the drug when added to a 
biological sample.  This binding will produce a measurable signal such as a change in 
absorbance (enzyme multiplied immunoassay technique, kinetic interaction of 
microparticle in solution) or change in radioactivity, radioimmunoassay.15,20,19   
 The enzyme multiplied immunoassay technique assay uses a drug-analog labeled 
enzyme in addition to the drug specific antibody which are mixed and added to the 
sample on a substrate of nicotinamide adeten dinucleotide (NAD).  When drug is present, 
it binds to the antibody preventing the drug-analog labeled enzyme from binding, making 
an active enzyme which converts NAD to its product increasing absorbance.  If no drug is 
present the drug-analog labeled enzyme binds to the antibody, effectively preventing 
enzyme activity and producing no change in absorbance.  The change in absorbance 
shows a positive detection of the drug of interest.  Figure 6 shows the reaction of the 
assay with and without the presence of the target analyte.20  
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Figure 6: Theory of enzyme multiplied immunoassay technique assay;2 When there is no 
drug present the antibody will bind with the drug analog which is attached to an enzyme.  
This process blocks the ability of the enzyme to catalyze a subsequent colorimetric 
reaction.  When drug is present, the antibody binds the target drug, freeing the enzyme 
conjugate, allowing enzyme activity to occur.20 
 When screening for benzodiazepines in urine, additional sample preparation is 
often required due to the high presence of glucuronidated conjugates over free drug in 
urine.5, 3, 10  These conjugates reduce sensitive in immunoassays as a result of the 
presence of both the undetectable conjugate and the free drug.  In order to remove the 
drug from the conjugate, enzyme hydrolysis with glucuronidase, often a one to two hour 
process, is recommended.10,9,12,17  Hydrolysis steps are often integrated into the kits that 
are sold for toxicological screening.18  In general, enzymatic hydrolysis is also 
recommended due to problems with an alternative procedure, acid hydrolysis, which can 
promote the conversion of certain benzodiazepines and metabolites into their 
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corresponding benzophenone.  These benzophenones are formed due to the cleavage of 
the diazepine ring at the N-4 position, causing an open ring structure which can reduce 
the specificity of the immunoassay.10,21  
Once the sample is prepared, the immunoassay process is performed using an 
automated plate reader.  Careful attention to the quality and quantity of the sample is 
important as false negatives or false positives can occur, which result from matrix 
interferences and the presence of other drugs in the patients’ system.  Cross-reactivity is a 
problem that results from the tendency of an assay to respond to compounds other than 
the one the assay is designed to detect.  An ideal immunoassay should have high cross-
reactivity with structurally similar compounds when designed to detect a class of drugs to 
prevent false-negatives and a low cross reactivity with other structurally similar 
compounds not part of the class of drugs to prevent false-positives.5  As previously 
mentioned, benzodiazepine assays commonly use antibodies that are specific for 
diazepam.  Because of structural differences with diazepam, certain benzodiazepines are 
poorly detected by these antibodies, resulting in false negative assays.  This was 
demonstrated by Augsburger et al. who found that urine samples which tested positive for 
lorazepam using gas chromatography/ mass spectrometry (GC/MS) could not be detected 
using standard immunoassay methods, developed with diazepam haptens.19  A later 
comparison of four different immunoassays for the detection of lorazepam found that 
none gave a positive result prior to hydrolysis, and only three gave some positive results 
after hydrolysis.22   
Low cross reactivity is not the only limitation of immunoassay screening.  Due to 
the variations in cross reactivity, many samples can also produce false negatives during 
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screening.  This is particularly true for drugs that are administered in the commission of 
DFSA as the victim may not report the crime for several days following the attack, and 
low doses of more potent benzodiazepines may have been used, further increasing the 
difficulty of detection.   Many immunoassays have cut-off levels between 50-300 
ng/mL.5,10, 12, 19-20  These cut offs are utilized to detect benzodiazepines at therapeutic 
concentrations (0.05-2 mg/mL)5  and minimize false positives.  Unfortunately the 
concentrations that may be observed in cases of DFSA can be lower.8  As mentioned 
above it has been suggested that diazepam detection should have a maximum detection 
limit of 10 ng/mL.11  To overcome these limitations of immunoassays, many toxicology 
laboratories have turned to GC/MS for screening and confirmation.  However, many 
hospitals and smaller clinical laboratories may not have access or training in this 
technology for sample screening. 
1.2.2 Gas chromatography mass spectrometry 
 Gas chromatography interfaced with mass spectrometry (GC/MS) is utilized by 
toxicology laboratories to allow for screening of a variety of drugs all at the same time.  It 
is often referred to as the “gold standard” for urine toxicology testing due to its 
specificity and selectivity.15  There are still some limitations to GC-MS  as a screening 
method for benzodiazepines including the problems of added sample processing through 
derivatization and longer analysis times when compared to immunoassay.  
Gas chromatography uses a carrier gas mobile phase to move volatile analytes 
through a chemically treated thermostated column (stationary phase).  Separation of the 
analytes occurs through partitioning between the mobile and stationary phases and are 
detected, in this case, by the mass spectrometer.  The drugs of interest must be volatile in 
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order for separation to occur.  In the case of benzodiazepines, they are not volatile and 
must be derivatized after extraction in order to be analyzed by GC/MS.  There are a 
number of different methods for derivatization.  Propylation followed by propinylation23, 
acetylation19, and silyation9 are some common derivatization methods to produce volatile 
products.  The products of these reactions must be well known in order to observe them 
through mass spectrometry.   
Mass spectrometry uses an ionization source to apply a charge to the volatile 
analytes as they move into the mass spectrometer.  Dependent on the ionization source, 
the ion will break apart into fragment ions which are separated in the mass analyzer by 
their mass to charge ratio and detected.26  The fragmentation patterns observed are 
consistent with a particular analyte and the drugs of interest can be identified.  The 
combination of GC/MS allows not only for the screening and identification of unknown 
drugs in a toxicology sample but is also sensitive enough to quantify.5   
A number of studies have used GC/MS to confirm the presence of 
benzodiazepines in urine samples which have been screened by immunoassays.9, 15, 19, 23  
Following acid hydrolysis and acetylation, GC/MS was performed to detect the various 
benzophenone and acetylated benzophenone products of a variety of consumed 
benzodiazepines.  Detection limits observed ranged from 2.5-250 ng/mL depending on 
the derivative detected and compounds not detected using immunoassays (lorazepam) 
were detected using GC/MS.19  After extraction from blood samples and a two-step 
derivatization of propylation followed by propionylation, GC/MS analysis was found to 
have limits of detection between 0.5-60 ng/mL and separation of 23 benzodiazepines and 
derivatives, however total time of analysis including sample preparation was two hours.23  
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While GC/MS is considered the “gold standard” it does have limitations including the 
time of analysis and the detection of derivatives rather than the parent benzodiazepine.   
1.3 Surface Enhanced Raman Spectroscopy 
 The present dissertation proposes a rapid screening method for the screening of 
benzodiazepines in urine using surface enhanced Raman spectroscopy (SERS).  As 
previously discussed, current methods of screening have a number of issues.  
Immunoassays have high cut-off levels and poor cross-reactivity with certain 
benzodiazepines.  They only provide information on whether or not a benzodiazepine is 
present, but cannot determine which particular benzodiazepine has been detected.   
Sample preparation can also be time consuming due to the need for hydrolysis steps.  
Immunoassays do have the benefit of automatic readers and they are not very expensive.  
GC/MS on the other hand is an expensive procedure, both in terms of equipment and us 
of the personal, especially when used in a hospital setting, where access to advanced 
analytical techniques and trained staff is limited.  Gas chromatography mass spectrometry 
also requires an additional sample preparation step involving derivatization of the 
benzodiazepine in order to improve stability and volatility.  Many of these disadvantages 
can be overcome with SERS.  This method provides limits of detection below the 10 
ng/mL upper limit in DFSA samples and a rapid analysis time from sample preparation to 
detection of less than 30 minutes.  In addition, SERS also provides information about the 
identity of an individual benzodiazepine instead of the generalized detection of a class of 
compounds through immunoassays.  Also, this technique is relatively inexpensive when 
compared to GC/MS.  Before discussing the development of this technique, the basic 
principles of Raman spectroscopy as well as SERS must be understood.   
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1.3.1 Raman spectroscopy 
 Raman scattering or effect was first described by C.V. Raman in 1928 as a “new 
type of secondary radiation”.24  He was able to observe what are now known as the anti-
Stokes Raman scattering by eye in a number of organic liquids, noting that the increase in 
energy emitted was different than other optical processes, such as fluorescence, which 
were already well known.24  Raman spectroscopy measures the scattering of photons that 
arise from the Raman effect.   
 Raman spectroscopy is a type of optical spectroscopy that involves the absorption 
of one photon (incident) and emission of a second photon (scattered) simultaneously, this 
process is known as scattering.  It is achieved by irradiating a sample molecule with a 
powerful laser source of visible or near-infrared (IR) monochromatic radiation.  There are 
two main groups of scattering processes, elastic and inelastic.  Elastic scattering is where 
the incident and scattered photons have the same energy (E), leaving the molecule at the 
same energy level after the scattering has occurred (Rayleigh scattering), and does not 
reveal any structural information about a molecule.  Inelastic scattering is where the 
incident and scattered photons are at different energy levels.25  The transition between the 
two states in the molecule relates to the energy difference.  Raman scattering is inelastic 
scattering which involves transitions between the vibrational/rotational energy levels.  
When no electronic transitions exist in a molecule, Raman scattering can still occur 
because it does not require direct absorption of a photon to a real higher energy state.  In 
these cases, the molecule is excited to a virtual state.  Compared to other forms of optical 
spectroscopy, such as absorption and fluorescence, scattering is a weak phenomenon.25  
Raman scattering can be subdivided by the energy of the incident photon in relation to 
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the scattered photon.  In the Stokes process, the scattered photon has less energy than the 
incident photon, while in the anti-Stokes process, the scattered photon has more energy 
than the incident photon.25  These processes can be described in a simplified Jablonski 
diagram in Figure 7.   
 
Figure 7: Simplified Jablonski diagrams for Rayleigh, Stokes, and anti-Stokes 
processes25-26. In Rayleigh scattering the energy difference is zero, while for the Stokes 
process the emitted energy is less than the incident and for the anti-Stokes process the 
emitted energy is greater than the incident.    
 Raman scattering does not just rely on the energy difference between the incident 
photon and the emitted photon, but also on the polarizability or the ability to induce a 
dipole in a molecule.25-26  To understand the polarizability, imagine a molecule in a static 
electric field.  This molecule is structurally characterized by the positions of the atoms 
and electrons present and their interactions with one another are in equilibrium.  When an 
external electric field is applied, like a laser, the constituents positions and properties can 
be modified resulting in a change of the dipole moment of the molecule, causing an 
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induced dipole moment.  These changes depend on the direction and magnitude of the 
electric field applied.  Polarizabilty is a measure of the responsiveness of the electrons in 
a molecule in the presence of an external electric field.  Generally organic molecules, 
such as drugs, are highly polarizable due to the large number of free electrons.  Taking 
into account polarizability, the Raman scattering can be described as the production of 
Raman scattered light by an induced Raman dipole.25 
Raman instrumentation measures the energies of the scattered photons in relation 
to the energy of the incident photons from a monochromatic laser source in the visible or 
near-IR range.  The Raman spectra produced consists of all three types of scattering 
previously described.  Of these, the strongest type of scattering is Rayleigh scattering.  
The Stokes and anti-Stokes scattering are much weaker are with the intensity of the 
Stokes scattering being greater than that of the anti-Stokes scattering.  These two forms 
of scattering are opposite but identical.  However, since the Stokes scattering is more 
intense, it is generally is the only part of the spectrum used.25-26   
 
Figure 8: Example Raman spectra25-26.  The Stokes and anti-stokes scattering occur at the 
same wavenumber but the Stokes shift is of higher intensity 
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The Raman spectrum corresponds to the relative Raman intensity as a function of the 
Raman shift measured in wavelength or energy (generally wavenumber cm-1).  The 
source irradiates the sample and scattering is measured by a charge coupled device 
(CCD) detector at 90˚ to the incident radiation to prevent viewing of the source radiation.  
The laser wavelength selected, in this study a 785 nm diode laser, is important to prevent 
fluorescence problems in the sample as well as absorption that may occur in colored 
samples.26  However, it is important to note that the wavelength of excitation does not 
affect the magnitude of Raman shifts.  The same compound will display identical Raman 
shifts regardless of the laser wavelength.25-26 
The Raman spectrum of a molecule contains peaks that correspond to the 
vibrational modes of a molecule, similar to infrared spectroscopy.  In fact, the infrared 
vibrational spectrum and Raman spectrum of a molecule should have a number of 
identical spectral peaks that correspond to vibrational modes in the molecule that are both 
IR and Raman active.  Differences do occur however when a particular mode in the 
molecule is only Raman active.  The Raman shift of a peak is equal to vibrational energy 
of the mode and the total intensity scattered by a given vibrational mode.  The frequency 
of vibrations can be determined through a quantum treatment, assuming that the 
transitions in vibrational energy levels are brought about by the absorption of radiation, 
and that the provided energy exactly matches the difference in the energy levels (ΔE) 
between the vibrational quantum states.  This occurs when the vibration causes a change 
in the dipole moment.26  Using the quantum treatment, the wavenumber of a given bond 
in a molecule can be calculated based on the expected vibrational frequency for a 
particular bond in a molecule, see Equation 1.  
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
k
c2
1             (1) 
Equation 1: where ν is the wavenumber of an absorption maximum (cm-1), k is the force 
constant for the bond (N/m), c is the velocity of light (cm s-1), and μ is the reduced mass 
(kg)26  
As a whole the Raman spectrum of a molecule will produce a unique molecular 
fingerprint related to the vibrational modes of the molecule.25-26  How these vibrational 
modes are determined and spectral peaks are identified will be further discussed in 
Chapter 7.   
One of the benefits of using Raman over IR spectroscopy is that water does not 
interfere with the Raman spectra of compounds, allowing Raman analysis to be 
performed in aqueous samples, such as urine.  The Raman spectra of water is weak and 
featureless, resulting from short-lived, picosecond, collision-induced spontaneous Raman 
scattering processes.27   Because vibrational scattering produced by other molecules lies 
well above this baseline, minimal interference occurs.27 
 As previously stated, Raman spectroscopy is not a sensitive technique, suffering 
from poor signal to noise ratios and low concentration sensitivity.  To overcome this low 
sensitivity problem and allow for analysis of low concentration samples, especially those 
in solution, surface enhanced Raman spectroscopy, which can increase the intensity of a 
spectra several orders of magnitude, has been employed. 
1.3.2 Mechanism of SERS 
 Surface enhanced Raman spectroscopy (SERS) was discovered by Fleischmann et 
al. (1974), who observed an intense Raman scattering from pyridine absorbed onto a 
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roughened silver electrode.  It was first thought that this was due to a large number of 
pyridine molecules being absorbed on the electrode surface.28  Two independent research 
groups demonstrated that the increased intensity Fleischman observed was the result of 
an enhancement of the scattered intensity while the molecules were absorbed onto the 
silver surface and not the effect of local increases in concentration.29,30 However, the two 
groups could not agree upon what caused the SERS mechanism and two main theories 
were developed and eventually combined.  In the simplest terms, SERS is the 
amplification of the Raman signals of molecules by several orders of magnitude through 
the interaction of the electromagnetic radiation with a metal surface that is in close 
proximity or adsorbed to the molecules.25  Physically, the main difference between SERS 
and traditional Raman spectroscopy is the addition of a metal surface or substrate.   There 
are two components that contribute to the activity of SERS, electromagnetic and 
chemical enhancement.  However, the main contributor to the SERS mechanism is due to 
the electromagnetic enhancement.   
 In order to discuss the SERS process in more detail, first, the optical properties of 
coinage metals, specifically gold (Au) and silver (Ag), which make up the SERS 
substrate must be discussed.  Optical properties of bulk metals are characterized by their 
dielectric function єሺ߱ሻ.  The dielectric function is related to the index of refraction, 
݊ሺ߱ሻ, by the equation ݊ሺ߱ሻ ൌ 	ඥєሺ߱ሻ.31  Each function depends on the frequency (ω) of 
the light because most materials respond differently when different frequencies 
(wavelengths, λ) of electromagnetic radiation are applied to the material.  Therefore, the 
dielectric function can either be represented as a function of ω or λ.31, 25  When 
examining the optics of material objects such as prisms and lenses, both the dielectric 
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function and the index of refraction are positive real numbers, however, in reality, the 
dielectric function of materials which are not transparent at a given wavelength will be a 
complex number.  The metals used in SERS have a dielectric function that is complex.32   
 The dielectric functions of Au and Ag are shown in Figure 9.   Both the real (a) 
and imaginary (b) parts of the dielectric function, єሺߣሻ, for each metal are represented 
from 300 – 900 nm to show the characteristics between the near-UV and near-IR 
wavelengths.31 There are a number of generalized characteristics of the real and 
imaginary parts of the bulk dielectric function for both metals.   
 
Figure 9: The real (a) and imaginary (b) parts of the dielectric function for Ag and Au.  
The imaginary part (b) is positive and of smaller magnitude while the real part (a) is 
negative in the visible range.31 
 For most of the visible range, the real part of the dielectric function of both metals 
is both large and negative.  This is one of the main reasons that Ag and Au are useful as 
plasmonic materials.  If the imaginary parts of єሺߣሻ are ignored, it can be said that the 
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real parts at long wavelengths follow a simple model for the dielectric function of a 
metal, the lossless Drude model, which predicts an approximately –λ2 dependence for the 
real part at long wavelengths.25, 31  The lossless Drude model predicts a dielectric function 
in the following form: 
є ൌ 	 єஶ ቀ1 െ ఠ೛
మ
ఠమቁ ൌ 	 єஶ ൬1 െ
ఒమ
ఒ೛మ ൰     (2) 
where ߱௣ ൌ 2ߨܿ/ߣ௣	is the plasma frequency (for Au and Ag ~280 nm) of the metal 
 
The similarity in the real portion of the dielectric function (Figure 8a) of both Ag and Au 
shows that these two metals have very similar electronic densities.  This is the 
approximate downturn of the real part of the dielectric function observed at longer 
wavelengths.   
 The imaginary part of the dielectric function єሺߣሻ cannot be ignored.  In reality, 
bulk metals are not lossless.  While Imሾєሺߣሻሿ is smaller than the real counterparts for 
both metals for most of the visible range, the effects of the imaginary portion of the 
function are important.  The imaginary portion is related to the absorption of the material 
(if the function is equal to zero, then the material does not absorb light).31  For sliver, the 
imaginary portion of the dielectric function can be generalized using the lossless Drude 
model.  For gold, this is more complicated because єሺߣሻ has additional contributions 
from other electronic transitions in the electronic band structure of gold.31  These 
interband electronic transitions cause the observed “double hump” structure in the 
imaginary portion of єሺߣሻ for Au (~400 nm) and the relatively higher absorption of Au 
(with respect to Ag) for wavelengths less than 600 nm (Figure 8b).  For wavelengths 
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greater than 600 nm, Au and Ag are comparable for the imaginary parts of єሺߣሻ, 
therefore, both materials are similar in their electromagnetic responses in the near- and 
far-IR range.31   
 Once the dielectric function єሺߣሻ is known, the electromagnetic properties of the 
metal can be calculated at different geometries.  This discussion will start with the 
simplest geometry, planar.  The normal reflectance (R) of Au and Ag are plotted in 
Figure 10 using the complex dielectric functions previously shown.  Gold has a 
reflectance of approximately 50% for wavelengths less than 600 nm, while silver is 
highly reflective, approximately 100%, over the entire visible range.  This is the reason 
for the color of planar gold, yellowish/red.31   
 
Figure 10: Reflectance at normal incidence for Ag and Au using the dielectric function 
shown in Figure 931 
 The local field intensity enhancement factor (LFIEF) at the surface must also be 
examined to discuss the SERS mechanism.  The LFIEF is described as how much the 
intensity of the electromagnetic field is changed with respect to the intensity that would 
have been observed at the same point without the metal.  The local field intensity at a 
given point is proportional to the square of the electric field amplitude at that point: 
|ܧሺݎሻ|ଶ.  The normalized value of |ܧሺݎሻ|ଶ with respect to the intensity of the incoming 
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field at a specific point (|ܧ଴ሺݎሻ|ଶ) is the local field intensity enhancement factor at that 
point.31  
ܮܨܫܧܨሺݎሻ ൌ |ܧሺݎሻ|ଶ/|ܧ଴ሺݎሻ|ଶ	    (3) 
The local field intensity enhancement factor expresses the change in local intensity at a 
specific point produced by the presence of objects which interrupt the electric field of 
light.  Therefore, any optical technique which depends on the intensity of light at a 
specific point (SERS) will be linked to the local field intensity enhancement factor.  It 
can be noted that the enhancement or quenching of an optical process depends on 
whether the local field intensity enhancement factor is greater than or equal to one, 
respectively.31 The local field intensity enhancement factor also depends on ω (or λ), due 
to the local field at a specific point depend on ω and can be rewritten as: 
	ܮܨܫܧܨሺݎ, ߱ሻ ൌ |ܧሺݎ, ߱ሻ|ଶ/|ܧ଴ሺݎ, ߱ሻ|ଶ    (4) 
 Another aspect of basic electromagnetic theory is the local field intensity 
enhancement factor at a flat surface for normal incidence and is solely determined by the 
dielectric function.  The local field intensity enhancement factor on the surface at the 
interface between the metal an air for both gold and silver are plotted in Figure 10.  An 
ideal lossless metal with 100% reflectivity will create a field on the surface, which will 
cancel out the incoming field and the transmitted field.  This sends the impacting 
electromagnetic wave back in the opposite direction from where it came.  Therefore, a 
low local field intensity enhancement factor at the surface is a consequence of high 
reflectivity.  In reality, the cancelation is not complete but is enough to produce a low 
local field intensity enhancement factor on the surface.  Figure 11 shows that the local 
field intensity enhancement factor is less than one across the visible range for gold, thus 
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showing a quenching in the intensity with the presence of gold.  Silver produces a local 
field intensity enhancement factor greater than one when the wavelength is less than 400 
nm, where Ag stops being a good deflector.31  
 
 
Figure 11: Local field intensity enhancement factor (LFIEF) at the surface of the metal 
for Ag and Au (at normal incidence).  Generally the LFIEF is less than 1 across the 
visible range.31  
 Aside from the highly reflective properties of these metals, it may seem that there 
is no major advantage to using these metals as photonic materials.  Molecules 
chemisorbed on a flat interface on these metals do not show much surface enhancement 
of the electromagnetic field when compared to other materials.  The usefulness of these 
metals is related to the shape and orientation of the metal surface and its effects on local 
electric fields.   
 To discuss these effects and their impact on the three dimensional spherical 
particles used in the present study, discussion must be made of the electromagnetic field 
around a cylinder with polarization Ei.  Maxwell’s equations must be solved subject to 
the boundary conditions which have previously been done for a number of simple 
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geometries to determine what happens to the field.25,33  For these purposes an 
approximation scheme, the electrostatic approximation, will be examined.   
 The electrostatic approximation can be represented schematically for a cylinder 
(Figure 12a).  The problem is solved at different ω’s (λ’s) using the complex dielectric 
function of the material at that wavelength.  The electrostatic approximation ignores the 
presence of the wavevector k (or the wavelength ߣ ൌ 2ߨ/݇) seen in Figure 12.  The 
applied electric field is uniform and oscillating up and down with frequency ω, instead of 
having a “wavelength”.  This approximation works when the size of the object is much 
smaller than the wavelength.  Typically, the approximation will mostly be valid for 
objects in the size range of 10 nm or smaller when the wavelengths used are between 
500-600 nm.31  It has also been used in some cases with even large objects that are 
beyond the size of these limitation.34  
 
Figure 12: Representation of localized surface plasmon resonances of a cylinder (a) a 
cylindrical metal object is impacted by an electromagnetic wave coming from the side 
with wavevector ki and polarization Ei (b) A constant electric field in the direction of 
polarization with no wavevector.  Point A is the boundary where the external field and 
the induced dipole are superimposed.31  
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 The exact solution of a cylinder with dielectric function єሺߣሻ can be determined 
by a number of factors.  The boundary conditions on the surface of the cylinder can be 
satisfied exactly by superimposing the external field E with an induced dipole centered at 
the origin (Figure 12b).  For points outside the cylinder, the electrostatic field looks like 
the external field superimposed with the dipole (p) at the origin.31  The magnitude of the 
induced dipole that solves the electrostatic problem is proportional to: 
݌	 ∝ ቀєሺఒሻିєಾєሺఒሻାєಾ	ቁ    (5) 
The most important detail of the proportionality in Equation 5 is the denominator.  As 
discussed previously єሺߣሻ is a complex number, thus, the full condition єሺߣሻ ൌ െєெ 
cannot be satisfied exactly (p  ∞).  At the wavelength where the real part of ሾєሺߣሻሿ ൌ
െєெ , which is the case for metals such as Ag, the magnitude of p will only be limited by 
how small the imaginary part of єሺߣሻ is.  This is observed as a resonance called the 
dipolar localized surface plasmon.  This resonance is induced solely by the shape of the 
object and the satisfying of boundary conditions.  Objects with different shapes will have 
different resonances.  Because metals have negative ܴ݁ሾєሺߣሻሿ spanning a wide range of 
magnitudes (Equation 1and Figure 9), this makes them ideal for satisfying a wide range 
of resonance conditions that occur in the solutions of the electromagnetic responses of 
many objects.31   
 When the geometry is changed to a metallic sphere, exact solutions of Maxwell’s 
equation (Mie theory) or approximate solutions can be used.  As with the cylinder, the 
electrostatic boundary conditions on the sphere are satisfied exactly by superimposing the 
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induced dipole at the origin p with the applied external field E.31   The difference is due 
to the 3D nature of the sphere that the magnitude of the induced dipole is proportional to: 
݌	 ∝ ቀ єሺఒሻିєಾєሺఒሻାଶєಾ	ቁ    (6) 
The resonance condition in the denominator has now changed, єሺߣሻ ൌ െ2єெ, and cannot 
be satisfied exactly due the presence of the imaginary portion of the dielectric function 
which is limited by how small ܫ݉ሾєሺߣሻሿ is at that wavelength.   
 If the surface of the sphere was to be examined, the places with the largest local 
fields are the two points along the axis that goes through the center of the sphere.  This 
axis is oriented in the direction of the external field.  Figure 13 show the axis in the 
sphere and the point labeled A is one of the largest local field points.  These are the two 
points where the induced dipole and the external field add up due to the superposition and 
approach a maximum.  When the local field intensity enhancement factor is calculated for 
point A on the sphere using the dielectric functions as a function of wavelength for both 
silver and gold, the resulting graph in Figure 13 is produced.  Note that the scale of the 
local field intensity enhancement factor is much larger than that for planar surfaces of 
these metals seen in Figure 11, due to the presence of the metal sphere.31  The local field 
intensity enhancement factor chart shows the intensity enhancement that a molecule 
would experience if it was located at that position on the sphere.  The peaks that are 
observed for both Ag and Au appear at the wavelength that the condition ܴ݁ሾєሺߣሻሿ ൌ
െ2єெ is met.  Silver has a stronger and narrower local field intensity enhancement factor 
when compared to Au because the condition is satisfied in Ag at a wavelength where the 
imaginary part of the dielectric function is much smaller than that of Au at its resonance 
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frequency.  This is why Ag is generally a better metal to use when compared to Au due to 
gold’s broad, weaker resonance.  This shows how intensities can be increased by large 
factors and can be tuned by changing the geometrical aspects of the metal.31   
 
Figure 13: Local field intensity enhancement factor at point A on a sphere of Au or Ag in 
the electrostatic approximation.  The largest local field intensity enhancement factors 
occur at the main symmetry axis in the direction defined by the polarization of the 
electric field.31 
 When using the electrostatic approximation the size of the sphere does not matter, 
however, when the size is between 30 – 100 nm the size is an appreciable percentage of 
the Raman excitation wavelength.  Therefore, there are a number of effects related to the 
size of the object.  First, dipolar localized surface plasmon resonances red shift as the size 
of the object increases.31  Dipolar localized surface plasmon resonances are also damped 
as size increases resulting in the broadening of the resonance and decrease in the local 
field intensity enhancement factor.  Lastly, larger sized objects can produce size-induced 
resonances that do not exist in the smaller size range.  These are related to the activation 
of multipolar resonances that do not couple to light effectively.31  To avoid these issues it 
is best to keep the size of the object as small as possible, below 30 nm.    
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 The induced dipole seen in the cylinder and the sphere allows for the introduction 
of another important topic related to SERS enhancement.  While this concept is for a 
single metal object, when there are two or more closely spaced objects there is the 
existence of coupled plasmon resonances.  If there are two cylinders that are several 
diameters apart from one another, they can be considered two independent cylinders, 
however, as the cylinders get closer together, the field produced by each of their induced 
dipoles start to interact.  The interaction changes the special configuration of the fields 
and shifts the energy of the resonances.  The couple resonance comes from the interaction 
of the dipoles of each individual cylinder.  Not only does the resonance shift but the local 
field intensity enhancement factor also increases between the two cylinders approach one 
another.31  These large enhancements are informally called hot spots.  In many cases of 
SERS they provide enough enhancement to detect single molecules.31  The large increase 
in the local field intensity enhancement factor at the hot spots is normally associated with 
the spatial localization of the resonance at the gap.  Figure 14 shows that the local field 
intensity enhancement factor is highly localized in the gap separating the two cylinders.  
When moving away from the center axis, and the hot spot, it is observed that the local 
field intensity enhancement factor greatly decreases.31   
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Figure 14: Formation of hot spots between two Ag cylinders. (a) Spatial distribution of 
the LFIEF between two Ag cylinders at 471 nm, red is the most intense while blue is the 
weakest.  Localized coupled plasmon resonance are the most intense.  (b) the variation of 
the LFIEF on the surface of the cylinder as a function of θ31 
The local field intensity enhancement factor is the increase in intensity that a 
molecule would experience at a specific point on the metal surface, therefore, all optical 
magnitudes that depend directly on the intensity are modified by the local field intensity 
enhancement factor (typically enhanced).  Raman scattering involves the interaction of 
two photons, one from the incident electromagnetic radiation from the laser and another 
re-emitted by the molecule.  If a molecule is placed on the surface of a metal where the 
laser field is enhanced through a local field intensity enhancement factor, more Raman 
processes will be produced.  The local field intensity enhancement factor will increase 
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ωL, the incident field, as though increasing the laser power.  Therefore, more scattered 
photons will be observed at ωS, the emitted field.  If the molecule is in a position that 
enhances the emitted field at ωS, the Raman intensity will also be increased because the 
emission is directly coupled to the excitation in the Raman process.  Due to the two 
photon process, the Raman process benefits from both the excitation and emission 
enhancements, local field intensity enhancement factor at both ωL and ωS.25,31  Therefore 
the enhancement process for SERS can be written: 
ܧܨ ൌ ܮܨܫܧܨሺ߱௅ሻݔ	ܮܨܫܧܨሺ߱ௌሻ    (7) 
Equation 7 is the simplest version of the SERS EF.  The SERS EF at a given point can 
then be determined by combining Equations 2 and 7:  
ܧܨ	~	ܮܨܫܧܨଶሺ߱௅ሻ ൌ 	 |ாሺ௥ሻ|
ర
|ாబሺ௥ሻ|ర     (8) 
Equation 8 shows the |ܧ|ସ approximation for the SERS enhancement and can be an 
estimation of the SERS enhancements in a single molecule located at point r.  In most 
experimental cases however, single molecules are not measured.  Rather, many molecules 
are spread across different places on the metal surface and have very different EFs.  
Going back to Figure 14, the distribution of the local field intensity enhancement factor 
observed close to and far away from the hot spot shows how molecules that differ in 
position can have very different EFs.  Therefore, surface-averaged SERS measurement 
are more appropriate to measure both the substrate performance as well as the SERS 
signal.31, 25  The metal particle, therefore is the main contributor to the SERS effect, not 
the molecule to be detected, though the molecule can have some effect and is related to 
the chemical enhancement that can be observed.   
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Chemical enhancements operate independently of the electromagnetic mechanism 
previously discussed and are a much smaller contributor to the SERS effect than 
electromagnetic enhancements.  These effects are related to the sample to be analyzed 
itself, such as molecular orientations and adsorptions.  These processes can increase the 
SERS enhancement but are not related directly to the SERS mechanism itself.  Chemical 
enhancements correspond to any modification of the Raman polarizability upon 
adsorption of the molecule onto the metal surface.25, 35  The most common mechanism of 
modification in polarizability is through charge-transfer, where the modified 
polarizability is more resonant with the excitation than the original polarizability.  This 
causes a natural increase in the Raman intensity due to the increase in resonance.  
Generally, chemical enhancement does not only appear for chemically bound molecules, 
it can also occur do to molecules being in close proximity with the metal surface.  It is 
important to note that chemical enhancement can also have a negative effect on the SERS 
enhancement.   For example, a negatively charged molecule cannot adsorb onto the 
surface of a negatively charge silver particle due to strong repulsions and no SERS signal 
will be produced.  This is important when dealing with different types of molecules using 
a single optimized SERS method.25   
1.3.3 Improvement of enhancement through aggregation 
 The largest SERS enhancements generally occur between two particles, where 
hot-spots form.  The hot spots a result of the coupled resonances of two particles in close 
proximity, thus increasing the electromagnetic field which was discussed previously 
(Figure 14).  In order to create these situations in colloidal solutions, these nano-particles 
must be aggregated to become useful SERS substrates.  The colloidal solutions prepared 
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should be stable solutions so that aggregation can be completely controlled by the 
addition of aggregating agents at an optimized concentration.25  Aggregation agent 
concentrations must be controlled in order to not exceed the critical coagulation 
concentration which causes particles to completely precipitate out of solution due to 
being highly aggregated.25   
 The most common types of aggregating agents are salts (active or passive).  
Passive salts are those that are not thought to interact strongly with the metals or other 
parts of the system, potassium nitrate (KNO3) for examples.  The addition of passive salts 
increases the ionic concentration in solution while decreasing the Coulomb interaction 
between the particles, thus producing aggregation.  Active salts, such as potassium 
chloride (KCl), change the ionic strength of the solution and can have additional 
interactions with other parts of the system, such as the metal substrate.  These active salts, 
mainly chloride containing salts, are most commonly used for colloidal SERS 
experiments and are their interactions are well understood.25,36,37 
 The interaction of chloride (Cl-) ions producing an “activated” SERS signal is 
known as “chloride activation” and refers to the additional increase in enhancement 
observed due to the presence of chloride ions in addition to the creation of hotspots 
formed during aggregation alone.  There is also additional anion enhancement as well.  
Chloride activation occurs by the displacement of the stabilizing agent on the surface of 
the metal nanoparticle by the chloride ions.  Chloride activation changes the surface 
charge of the particles, increasing the negative charge, and changes the ionic strength of 
the solution.  Chloride ions can also modify the adsorption properties of the SERS 
analyte, helping the adsorption of the analyte to the SERS surface.  These ions can also 
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increase the chemical enhancement property of SERS.25,37  While the anion-enhancement 
is well studied, the effect of the cation of the salt has only recently been shown to have an 
effect.  It has been found that the smaller the cation (even with the same number of 
chloride ions) the larger the SERS enhancement.6,37 
 It is important to note that while SERS parameters can be generalized, the 
optimum conditions are highly variable.  While some trends can be established, there is 
no simple relationship between colloids, aggregating agents, and analytes.  This has been 
previously discussed in a number of optimization papers.36,37,38  When designing a SERS 
experiment, optimization has to be carried out between analyte and aggregating agent as 
well as with colloidal solutions used regardless of the similarity in analytes.37,38 
1.3.4 Nanoparticle formation and properties 
The two main parameters in a SERS experiment (though there are many more) are 
the analyte and the metallic substrate.  In order to produce the highest signal 
enhancement, the selection of the metallic substrate is critical.  Generally, metal 
substrates that produce the strongest plasmon resonances (local field intensity 
enhancement factor) are selected.  As discussed above, the plasmon resonance response 
of the substrate is the main facilitator of the SERS enhancement.  The resonance is 
wavelength dependent, therefore, substrate selection should be determined based on the 
laser wavelength to be used.  The wavelength selection does not affect the magnitude of 
Raman shifts, as Raman shifts are only dependent on the energy difference between the 
incident and emitted photon after interaction with the molecule.  The same compound 
will display identical Raman shifts regardless of the laser wavelength.25, 26  A good 
substrate at one wavelength may be very poor at another.  Silver and gold are the main 
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metals used in SERS experiments due to sustaining plasmon resonances in the 
visible/near-IR range used in Raman systems observed in Figure 13 of the previous 
section.25   If silver is used as the SERS substrate, an ideal wavelength would be at 
approximately 350 nm, this is where Ag produces a maximum local field intensity 
enhancement factor with a very narrow range for a spherical particle.  If gold is selected 
as the SERS substrate for a spherical particle, a wider range of laser wavelengths can be 
used due to the broad local field intensity enhancement factor from approximately 500 – 
850 nm.   Gold produces a maximum enhancement when the wavelength selected is 
approximately 550 nm, however, this maximum is well below that of Ag at its optimal 
wavelength.31 
Silver and gold colloidal solutions, are produced by reduction of the metal 
containing salt by a number of methods.39,36  Colloidal solutions are advantageous over 
solid support SERS substrates due to their quick, reproducible synthesis, as well as 
having the capability to provide a fresh substrate to perform each subsequent analysis.  
There is no further complication of removing an analyte from a substrate.  The colloids 
exist in solution due to stabilization either by columbic repulsions among the particles or 
by the introduction of a stabilizing agent which coats the surface of the particles and 
prevents aggregation.25  In some cases, the reducing agent can also serve as the 
stabilizer.39  In general, gold particles are more easily stabilized then silver over longer 
periods of time (greater than a year).   Citrate-reduced colloids are the most commonly 
generated nanoparticles for SERS analysis.   
Citrate-reduced colloids are commonly referred to as “Lee-Meisel” colloids 
because of their work providing the initial synthesis method.39   The colloids are prepared 
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by bringing a solution of silver nitrate (AgNO3) or chloroauric acid (HAuCl4) to boiling, 
adding a 1% by weight sodium citrate solution, which acts as the reducer and stabilizer, 
and refluxing for an hour and bringing to room temperature.39  The procedure produces a 
silver solution with a grey-yellow color and a UV/Vis  absorption maximum between 
400-430 nm and a gold solution with a wine red color and a UV/Vis absorption 
maximum between 520-530 nm.25,39 Other reducing agents have been applied, in 
particular to the synthesis of silver nanoparticles.  The most common of which is sodium 
borohydride, however, these particles are not as stable as sodium citrate reduced 
colloinds.25,36,40  In all these methods of synthesis, the formation of the particles is not 
completely understood.  It is proposed that colloid formation begins by a nucleation 
process, which then triggers the growth of the particle to a certain size and shape.  This 
can be controlled by limiting the amount of metal or reducing agent present, thus 
stopping the reaction or by changing the temperature of the reaction quickly.25 
Once colloidal solutions are synthesized they can be characterized in a number of 
ways.  The first, most simply is using scanning electron microscopy (SEM) to evaluate 
the size and shape of the particles.  The SEM analysis can be performed on colloidal 
solutions by first drying the solution onto the appropriate substrate and taking an image 
of the now clustered particles.  The SEM gives a look at the basic shape and size of the 
particles individually but does not provide information about the whole solution or how 
the particles appear in the whole solution.   To obtain information on the entire solution, 
optical or light-scattering methods such as UV/Vis spectroscopy are often employed.25 
Ultra-violet/visible spectroscopy provides additional information about the 
colloidal substrate.  The UV/Vis absorption maximum of colloidal solutions, is associated 
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with a resonant optical response at the wavelength which corresponds to the localized 
surface plasmon resonance.    Due to SERS occurring as a result of the interaction with 
the localized surface plasmon resonance, when the incident laser is at the same 
wavelength as observed for the UV/Vis absorption maximum, the largest SERS 
enhancement is expected.25  These measurements can also be used for quick “quality-
control” of different batches of particles as it is dependent on the shape but not the size of 
the particles.25  
Dynamic light scattering (DLS) is used to measure the size distribution of colloids 
in solution.  The DLS technique relies on the measurement of intensity fluctuations in the 
light scattered by a monochromatic source.  The movement of the colloids (Brownian 
motion) is directly related to these fluctuations and the particle size can be indirectly 
determined by estimating the diffusion coefficient from the intensity fluctuations.  The 
DLS technique is widely used as a quick characterization technique for the size and 
dispersion of colloidal solutions.25    
1.4 SERS for Drug Detection 
Surface enhanced Raman detection has been applied to a number of different 
drugs of abuse, either as standards or after a separation technique.  In previous work by 
Cîntã et al., the analysis of diazepam and nitrazepam was performed on silver colloid 
surfaces in aqueous solution.40  The nanoparticles were synthesized using borohydride 
reduction.  The drugs were detected and identified at a concentration of approximately 30 
ng/mL with excitation wavelength of 488 nm.   Though the structures of these two 
compounds are very similar, they can be easily distinguish on the basis of differences in 
Raman vibrational frequencies.40   
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Surface enhanced Raman spectroscopy has been employed for the analysis of 
trace identification of some controlled substances.41,42  Silver nanoparticles were used to 
detect morphine, codeine and hydrocodone in trace quantities with NaCl aggregation.41  
Nanoparticles, aggregating agent, and sample were applied directly to microscope slides 
for analysis.  The spectra produced provided sufficient spectral information to 
differentiate these three structurally similar molecules as well as providing information 
on to how the molecules interact with the nanoparticles.  Detection limits were not 
determined and spectra were produced with the addition of 1μg of drug of interest.  Fox 
et. al., combined electrostatic lifting with SERS analysis.42  Ultra-trace analysis was 
performed by the electrostatic lifting of drug residues from mixtures of drug in sand (15% 
by weight) directly onto gold plated Mylar lift films.  Surface enhanced Raman 
spectroscopy was then performed on the films.  This method shows the applicability of 
SERS to trace level drug detection.42 
Surface enhanced Raman spectroscopy has also been applied in the analyses of 
other drugs of abuse, such as sulfa drugs, amphetamines, cocaine, and heroin.43,44,45,46,47  
Sutherland et al. were able to detect the sulfa drugs sulfadiazine, sulfamerazine, and 
sulfamethazine by SERS using silver colloidal dispersions.  These dispersions were 
prepared using the common sodium borohydride reduction method with no addition of 
any aggregating agent.  They found detection limits below 10 ng/mL.46   
Other types of drugs mentioned above were analyzed by applying the drug sample 
directly onto a solid planar SERS substrate either directly or following a liquid separation 
technique rather than using colloidal solutions.   Bell and colleagues have performed a 
number of studies describing the analysis of solid tablet samples amphetamines and 
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amphetamine derivatives by Raman spectroscopy and SERS.48,49,50,51,52  Using SERS, the 
group was able to improve the detection of low levels of amphetamines. For example, 
they were able to observe a concentration of 38 μg/mL in the detection of 2,5,-
dimethoxy-4-bromoamphetamine (DOB)  in lactose incipient, which is well below the 
concentrations commonly seen in illicit tablets (10 mg per tablet).  The preferential 
enhancement was due to the selective adsorption of the DOB to the silver colloids over 
that of the lactose, enhancing the Raman spectra of the DOB to overwhelm that of the 
lactose.52  The selective enhancement can be applied to complex matrixes by using a 
substrate where drugs of interest are preferentially absorbed onto the substrate surface 
over the solvent and other components of the matrix.  
Surface enhanced Raman spectroscopy has also been applied to the analysis of 
drugs following a liquid separation technique, such as high performance liquid 
chromatography (HPLC) or capillary electrophoresis (CE).43,44,45,53,54 Often testing for the 
presence of drugs involves an analysis in physiological fluids. In such situations, the 
SERS analysis would be complicated by the presence of interferences such as proteins, 
therefore, the small quantity of drug present must be extracted and cleaned up prior to 
using SERS detection.43,44,45  Cleanup can also include preconcentration of the sample to 
improve the sensitivity of the analysis.  HPLC has been utilized as a separation technique 
prior to SERS for the analysis of cocaine, heroin, amphetamines and 1,4-benzodiazepines 
by Schneider and coworkers.43,44,45  Each study shows that following a liquid-liquid 
extraction from biological fluids, HPLC can separate a sufficient amount of material for 
SERS off-line detection (1 μg/mL).  The choice of eluent is extremely important due to 
competition with the analyte for adsorption to the SERS substrate.  Many organic eluents, 
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such as acetonitrile, compete with the analyte for the SERS substrate.  However, other 
buffers and eluents such as phosphate and methanol, do not compete for the SERS 
substrate and in fact, the increasing salt content can enhance the SERS signal.  In these 
investigations, the eluent was sprayed onto a substrate followed by SERS analysis.  The 
substrates were typically colloidal gold or silver deposited onto the surface of a microtiter 
plate or roughened glass microscope slide.   
Capillary electrophoresis/SERS has also been developed with at-line coupling 
similar to those methods performed by HPLC.54  In the case of CE, the run buffer was a 
formic acid solution with no organic modifier.  Dyes were detected using a UV detector 
and then deposited on a substrate following elution from the CE column.  The main 
benefit of using CE as a separation technique over HPLC is the ability to use aqueous 
eluents instead of aqueous/organic mixtures.  Removing the organic solvents provides 
less SERS interference and adsorption competition.   
Another separation technique that has been used with SERS is solid phase 
extraction followed by elution of drugs of interest into sol gel filled capillaries that were 
doped with gold and silver particles.55  This study was able to detect eighty drugs of 
abuse, including a number of benzodiazepines and other DFSA drugs, from simulated 
saliva samples, to a detection limit of 50 ng/mL for cocaine.  Five other drugs were 
tested, of them, diazepam was detected at a limit of 1000 ng/mL, which is well above 
required detection limit for this type of drug.  In this method, analytes were dried in the 
sol gel filled capillaries, rather than analyzed as liquids.55 
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2. GOALS AND OBJECTIVES 
The goal of this thesis was to produce a surface enhanced Raman procedure 
capable of providing sensitive detection of benzodiazepines from biological samples as a 
rapid and universal alternative to traditional immunoassays.  The procedure would permit 
drug speciation, making it particularly useful in situations such as DFSA where quick 
determination of the unknown chemical agent is important.  Such procedures should 
require minimal sample input and be sufficiently rapid and sensitive to permit use in 
point of care situations.    
The study includes three main objectives.  The first objective was to optimize the 
detection of benzodiazepines on SERS substrates.   This included the development of 
optimal SERS metal substrate as well as the determination of best possible aggregating 
agent to permit easy coupling of Raman signal to the analyte.  The second part of the 
study was to investigate possible interferences commonly observed in urine samples of 
drug facilitated sexual assault and to determine the extent to which these compounds 
interfered with the SERS analysis of benzodiazepines.  The final part of the study was to 
validate the method and determine an extraction technique for use with simulated 
toxicological samples.  The overall procedure was validated using a panel of 
benzodiazepines implicated in drug facilitated sexual assault.  The validation process 
included spectral analysis of the Raman shifts for individual benzodiazepines, 
determination of analytical figures of merit, and analysis of simulated/spiked 
toxicological samples.    
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3. DETERMINATION OF SURFACE ENHANCED SUBSTRATE 
3.1 Introduction 
 There are a wide variety of possible surface enhanced Raman active substrates 
that can be used in the development of an optimized SERS system.  To simplify the 
optimization, only the most commonly used metals, silver (Ag) and gold (Au), due to 
their optimum optical properties in the laser range applicable for SERS, were examined.25    
The goal of the overall method is to provide a quick screening technique for 
benzodiazepines in urine samples and due to the lack of interference in the SERS 
spectrum by water, colloidal solutions will provide a quick, inexpensive, disposable 
SERS substrate to provide analysis of such aqueous solutions as urine.   
A number of methods have been described for the synthesis of gold and silver 
spherical nanoparticles.  The most common of which is the Lee Meisel method involving 
the reduction of the metal containing salt with sodium citrate.39  Other methods involving 
reduction of metal salts involve using sodium borohydride or hydroxylamine 
hydrochloride as the reducer.36,56 In order to assess the quality of the particles in relation 
to benzodiazepines, chlordiazepoxide was used due to its solubility in water, thus not 
introducing any possible interfering organic solvents.  Aggregating agents of magnesium 
chloride were prepared at a commonly reported concentration.36  Chlordiazepoxide HCl 
was also prepared in varying concentrations of methanol in order to determine the 
maximum concentration of methanol that can be used for dissolving other 
benzodiazepines without interfering the their SERS spectra.  
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3.2 Experimental 
All solutions were prepared with ultrapure water.  Glassware was cleaned with 
detergent followed by deionized water and then methanol.   
3.2.1 Nanoparticle Synthesis  
Three methods of synthesis were performed for silver nanoparticles while only 
one was prepared for gold.  The first silver synthesis (AgI) is based on the Lee Meisel 
method.  Two mL of a 1% trisodium citrate solution was added to 100 mL of 1 mM 
AgNO3 was heated to boiling.  Boiling was maintained for one hour under reflux then 
cooled to room temperature and brought to a volume of 200 mL with deionized water 
producing a dark grey solution with a relative concentration of 0.2 mM silver.39,36  The 
gold colloidal solution was also based on the Lee Meisel method.  Two mL of a 1% 
trisodium citrate solution was added to 50 mL of 0.5 mM HAuCl4 which was heated to 
boiling.  Boiling was maintained for thirty minutes under reflux then cooled to room 
temperature and diluted to 50 mL with deionized water producing a clear, dark red 
solution.39,36   
The second silver synthesis (AgII) is based on the Creighton method.  Twenty 
five mL of a 1 mM AgNO3 solution was added in 5 mL aliquots to 75 mL of an ice 
cooled 2 mM NaBH4 solution with vigorous stirring.  After the addition of all the silver 
nitrate solution stirring was continued for an additional 10 minutes.  Twenty five mL of 
deionized water was added to the resulting solution producing a brown solution with a 
relative concentration of 0.2 mM silver.57,36  The third silver synthesis (AgIII) is based on 
the Leopold Lendl method.  Four and a half mL of 0.1 M NaOH was mixed with 5 mL of 
a 60 mM solution of hydroxylamine hydrochloride.  The resulting solution was added 
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rapidly to 90 mL of vigorously stirred 1.1 mM AgNO3 and stirring was continued for 10 
minutes until a milky grey solution was produced.  To this resulting colloid solution, 395 
mL of deionized water was added to produce a relative concentration of 0.2 mM silver.56  
Particles were characterized by using three main analytical techniques.  The 
ultraviolet-visible absorbance (Varian Cary 100 Bio UV-visible spectrophotometer) was 
measured to determine relative size and optimum incident laser.  Colloidal solutions were 
added directly to quartz cuvettes and measured.  Physically particle size was measured 
using scanning electron microscopy (JEOL JSM 5900LV, 3.0 nm resolution).  Colloidal 
solutions were centrifuged for 10 minutes and supernatant was removed and particles 
were dried overnight.  The resulting pellets were applied to carbon studs for SEM 
imaging.  Dynamic light scattering was performed on gold nanoparticles for further size 
verification with three runs each with 16 scans.   
3.2.2 Sample Preparation 
 Magnesium chloride at a concentration of 1.67 M was prepared in water for use as 
a sample aggregating agent.  Aggregating agents were further analyzed in Chapter 4.  
Chlordiazepoxide HCl dilutions were prepared in deionized water from 50 – 50,000 
ng/mL.  Chlordiazepoxide HCl was also prepared at a concentration of 25,000 ng/mL in 
varying concentration of methanol (1% - 10%) in water.   
 The SERS spectra were obtained with a Perkin Elmer Raman Station 400F with 
785 nm excitation for four spectral scans each at a 10 second exposure.  The power at the 
sample surface was 100 mW.  Samples as prepared below were transferred to SERS 
inactive quartz cuvettes for analysis.  For SERS experiments, 980 μL of gold colloids 
were placed in sample vial followed by 10 μL of the aggregating agent.  This was 
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vortexed for 30 seconds.  Ten μL of sample solution was then added and vortexed for 30 
seconds.36  
3.3 Results and Discussion  
3.3.1 Size characterization of particles 
All particles observed were spherical in shape with a range of sizes (20 – 30 nm) visible 
in the SEM micrographs.   
AgI 
 This synthesis method, sodium citrate reduction, produced a dark grey solution.  
The UV-visible absorbance showed a maximum wavelength at 347 nm and the SEM 
micrograph measured particle sizes consistent with approximately 20 nm.  Figure 15 
shows these results. 
 
Figure 15: UV-visible absorbance and SEM micrograph of AgI particles 
AgII 
 The second synthesis method, sodium borohydride reduction, produced a brown 
solution.  The UV-visible absorbance showed a maximum wavelength at 393 nm and the 
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SEM micrograph measured particle sizes consistent with approximately 20 nm.  Figure 
16 shows these results. 
 
Figure 16: UV-visible absorbance and SEM micrograph of AgII particles 
AgIII 
 The third synthesis method, hydroxylamine hydrochloride reduction, produced a 
milky grey solution.  The UV-visible absorbance showed a broad absorbance band with 
maximum wavelength at 425 nm and the SEM micrograph measured particle sizes 
consistent with approximately 20 nm.  Figure 17 shows these results. 
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Figure 17: UV-visible absorbance and SEM micrograph of AgIII particles 
Au 
 The gold synthesis method, a sodium citrate reduction, produced a clear dark red 
solution.  UV-visible absorbance showed a maximum wavelength at 522 nm and the 
SEM micrograph measured particle sizes consistent with approximately 30 nm.  Figure 
18 shows these results. 
 
Figure 18: UV-visible absorbance and SEM micrograph of gold particles 
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In addition, dynamic light scattering was performed on these gold nanoparticles.  Figure 
19 shows the size distribution curve of the particles, ranging from 10 – 80 nm in size with 
an average particle size of 28 nm in diameter.   
 
Figure 19: DLS size distribution of gold nanoparticles; particles ranged in size from 10-
80 nm with an average particle size of 28 nm 
3.3.2 Surface enhanced Raman validation 
 First it was determined whether these particles would produce any extraneous 
spectra that would have any interference with the drugs to be analyzed in further studies.  
Water was added to the particles and the aggregating agent as described in the methods 
and the SERS spectra were obtained.  These blanks produced flat baselines with a large 
peak at 200 cm-1 due to water, however this peak does not interfere in the spectral range 
necessary for drug analysis (1800 – 400 cm-1). 
Chlordiazepoxide HCl was used as a model compound for the optimization of 
nanoparticles for their use in SERS.  The compound is water soluble and does not require 
potentially interfering organic solvents for dissolution.  Samples of chlordiazepoxide 
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were added to prepared nanoparticles using MgCl2 as an aggregating agent as described 
in the methods.   
 The three silver particles all produced similar spectra for chlordiazepoxide with 
varying intensities under the same conditions.  The gold particles, however, produced a 
Raman spectra that was significantly different that those produced with silver particles, 
Figure 20.  This is likely due to different interactions between the drug and the particles.  
As a result of the much reduced number of peaks in the silver spectrums, it is likely the 
drug is binding the surface of the silver particles while only being in close proximity to 
the surface of the gold particles.25   
 
Figure 20: SERS comparison of chlordiazepoxide between four synthesized particles.  
While some spectral information is observed for Ag I particles, Au provided the highest 
intensity peaks as well as more spectral information for chlordiazepoxide when compared 
to the Ag particles. 
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 Limits of visible detection were also examined to determine whether SERS 
spectra could be obtained below the high concentrations prepared.  In all cases the silver 
nanoparticles did not produces a SERS spectra for chlordiazepoxide at any concentration 
prepared below 50,000 ng/mL.  On the other hand, the gold particles produced spectra at 
all concentrations tested, down to 50 ng/mL.  The overall goal of this technique is to be 
able to detect benzodiazepines at a concentration of 10 ng/mL or below.  Therefore, the 
gold nanoparticles were determined to be the optimum colloids for the analysis of 
benzodiazepines and were used in the following study. 
3.3.3 Methanol Study 
 Chlordiazepoxide HCl was prepared at varying concentration of methanol (1% - 
10%) as well as solutions of methanol at the same concentration without any drug in 
water.  The SERS spectra were obtained for all samples.  Figure 21 shows the SERS 
spectra of   pure methanol, 10% methanol in water and 25,000 ng/mL chlordiazepoxide 
HCl in 10% methanol.   
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Figure 21: Comparison of methanol spectra with chlordiazepoxide HCl in 10% methanol. 
At 10% methanol with the drug, any slight methanol peaks are completely suppressed by 
the drug.   
It was found that while methanol concentrations without the addition of drug did 
provide very slight methanol spectra at a concentration of 10% methanol, no methanol 
peaks were observed in the SERS spectra of chlordiazepoxide HCl up to a concentration 
of 10%.  Due to this, all subsequent analyses of benzodiazepines were prepared in 10% 
methanol in water as it provides sufficient organic solvent to facilitate dissolving the drug 
and yet is not an interference in the SERS spectra of these drugs.   
3.4 Conclusions 
 It was determined that the optimum SERS substrate for the analysis of 
benzodiazepines are spherical gold colloidal solutions prepared by a modified Lee Meisel 
method.   This is due to their ability to provide spectra of chlordiazepoxide, the model 
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benzodiazepine used, at the minimum concentration prepared here, 50 ng/mL.  The 
intensity of these peaks were still well above the baseline, therefore, the Au particles 
should allow for detection of benzodiazepines below the 50 ng/mL concentration 
prepared here.  All three Ag particles prepared could not provide spectra at the 50 ng/mL 
concentration prepared here, making these Ag particles not useful for analysis of 
benzodiazepines.  This issue is due to the wavelength of the laser in use, 785 nm.   As 
discussed in Chapter 1.3.2, the SERS mechanism relies heavily on the local field intensity 
enhancement factor (LFIEF) experienced by a molecule on the metal surface which is 
dependent on the wavelength of incident energy.  Figure 13 shows that for silver, the 
highest local field intensity enhancement factor on spherical particles occurs in a very 
narrow wavelength range with a maximum local field intensity enhancement factor at a 
wavelength of ~350 nm.  At 785 nm, the local field intensity enhancement factor is close 
to zero.  On the other hand, gold produces a high local field intensity enhancement factor 
over a very wide wavelength range with a maximum at ~550 nm.   At 785 nm, the local 
field intensity enhancement factor is approximately 11.31  Here, we have shown that 
experimentally at an incident wavelength of 785 nm, gold and silver follow the theory 
and Au is the better substrate.      
It was also determined that benzodiazepines can be dissolved in a solution up to 
10% methanol without interference.    When dissolved in a concentration about 10% 
methanol, the spectral peaks from the methanol begin to invade the SERS spectra of the 
drug and present a problem.  These parameters were used in all remaining studies.  While 
the silver particles prepared did produce some enhancement, the observable limits of  
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detection are well above those that are need  to use this technique in the analysis of drug 
facilitated sexual assault samples (10 ng/mL).   
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4. COMPARISON OF AGGREGATIGN AGENTS FOR THE SURFACE-
ENHANCED RAMAN ANALYSIS OF BENZODIAZPINES 
Doctor, E.L.; McCord, B., Comparison of aggregating agent for the surface-enhanced 
Raman analysis of benzodiazepines. Analyst 2013, 138 (20), 5926-5932 – Reproduced 
with permission of The Royal Society of Chemistry.6   
4.1 Abstract 
Benzodiazepines are among the most prescribed compounds and are commonly 
present in many toxicological screens.  They are also of concern forensically in cases of 
drug facilitated sexual assault. Currently these compounds are predominantly analyzed 
using immunoassay techniques; however more specific screening methods are needed. 
This paper demonstrates the applicability of surface enhanced Raman spectroscopy as a 
method for the analysis and detection of benzodiazepines.  The procedure involves 
mixing urine extracts with gold nanoparticles and appropriate aggregating agents for 
trace detection of these compounds and their metabolites.  In this paper we will discuss 
the optimization of various parameters of this technique as well as its application to 
screening urine samples. 
 Eleven different benzodiazepines and metabolites were examined, including 1,2-
triazolo-benzodiazepines and 1,4-benzodiazpines.  Experiments were performed using 
four different chloride salts, MgCl2, CaCl2, KCl, and NaCl, as aggregating agents for the 
colloidal gold nanoparticles.  Overall it was found that each aggregating agent produced 
different levels of signal enhancement for each drug.  MgCl2 provided the lowest limit of 
detection at 2.5 ng/mL, and linearity over a wide range of concentrations for a variety of 
drugs chosen.   It was also determined that the optimum MgCl2 concentration was 1.67M 
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 This method has shown the applicability of SERS for the detection of trace 
quantities of benzodiazepines in aqueous solutions as well as the optimization of the 
technique over a wide range of compounds.  This technique can be utilized in the 
detection of trace benzodiazepines in toxicological samples following extraction of the 
analyte. 
4.2 Introduction 
Raman spectroscopy’s use as an analytical technique in forensic science 
laboratories has increased in recent years.  The technique utilizes an intense laser to 
induce dipole moments in selected molecules.   Inelastically scattered light from the laser 
is measured as a shift in frequency from the incident beam frequency and the resulting 
intensity profile produces the Raman spectrum.25  Raman spectroscopy offers some 
analytical advantages over other common spectroscopic techniques.  Powder samples can 
be analyzed directly without sample preparation.58,49,59,60,61,62  This has been shown to 
provide rich spectral information that can distinguish compounds with closely related 
structures.60,61,62  Raman instrumentation can also be coupled with an optical microscope 
to study small particles.58,49,59  Lastly, unlike infrared spectroscopy where water is a 
major interference in the spectral analysis, samples can be run in an aqueous 
environment.43   Conventional Raman spectroscopy is not without its drawbacks.  
Fluorescence can obscure the spectrum of the analyte and unless the analyte is at high 
concentrations, the Raman signal is often very weak, limiting the trace detection of drugs.  
Surface-enhanced Raman spectroscopy (SERS) overcomes the limitations by providing 
an enhanced signal several orders of magnitude over conventional Raman spectroscopy 
and quenching fluorescence.25   
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SERS requires the use of a SERS active metal substrate, commonly gold, silver, 
or copper, such as colloidal metal particles in aqueous solutions or roughened metal 
films.  The interaction of the analyte with the substrate causes an increase in signal 
intensity.   Colloidal solutions are advantageous due to their simple synthesis in batches 
and relatively low cost.  They also provide a fresh surface for each analysis preventing 
contamination between samples.25  To further increase the enhancement of the SERS 
signal, aggregate solutions are used.  These agents are salt solutions which cause the 
nanoparticles to amass and form hot-spots which increase the signal intensity.  Chlorine 
salts generally provide the greatest enhancement for two reasons.   The chlorine ions 
displace the stabilizing agent to cause aggregation and they affect the ionic strength of the 
surrounding solution changing the surface charge of the substrate, therefore increasing 
the signal intensity.25 
The technique of SERS has been examined for use in the detection of controlled 
substances such as for narcotics, amphetamines, nicotine, and 
benzodiazepine.43,47,45,44,50,51,48,49,41, 52-54, 63, 41  Often this analysis is done with dried drug 
samples, where the controlled substance is dried onto the SERS active substrate.  
However, SERS has the potential for use in aqueous solutions which can be adapted for 
the detection of these controlled substances in toxicological samples.   SERS detection of 
diazepam and nitrazepam was performed on silver colloid surfaces in aqueous solutions 
at a concentration of 30 ng/mL.40   
Toxicology laboratories are inundated with drug-facilitated sexual assault cases 
that require quick screening for over 40 different possible compounds.  There has been a 
significant increase in the prevalence of benzodiazepines in these types of case 
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submissions.  Benzodiazepines are a class of controlled substances that are commonly 
prescribed medication for anti-depression and anti-anxiety.  The effects these compounds 
have on the central nervous system such as amnesia, drowsiness, impaired coordination, 
and confusion have resulted in their increasing use in the commission of drug-facilitated 
sexual assault. The most common procedure used for the initial detection of these 
compounds is the immunoassay, however, this technique has many disadvantages when 
used in the determination of benzodiazepines.  First, in many commercially available 
immunoassays, including enzyme multiplied immunoassay technique II, kinetic 
interaction of microparticle in solution and radioimmunoassay, the cutoff levels for 
benzodiazepines fall between 100 and 300 ng/mL.19,20  While these levels may be 
consistent with overdose or therapeutic levels, in cases where benzodiazepines are used 
during drug facilitated sexual assault, the concentrations observed are much lower (50 
ng/mL), and immunoassays may produce a false negative for the presence of 
benzodiazepines.  Secondly, some benzodiazepines have a poor cross-reactivity with 
immunoassay systems, such as lorazepam.19, 20  Due to these problems, many laboratories 
also employ GC-MS screenings for benzodiazepines.  Sample preparation for the GC-MS 
of the benzodiazepines involves not only extraction of the drugs from the biological 
matrix but also for some benzodiazepines, derivatization is necessary in order to produce 
volatile compounds, further complicating the procedure.19,64   
In this study, eleven different benzodiazepines were examined from two of the 
main classes of benzodiazepines, 1,2-triazolo-benzodiazepines and the 1,4-
benzodiazpines, as well as a number of metabolites.  Their base structures can be seen in 
Fig. 22 while substituents for individual drugs are seen in Table 2. 
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Figure 22: Base structures of 1,4-benzodiazepines (A) and 1,2-triazolo-benzodiazepines 
(B) 
1,2- Triazolo- benzodiazepines R1 X R4 R2’ R8 
Alprazolam -CH3 =N- -H -H -Cl 
Midazolam -CH3 =C- -H -F -Cl 
Triazolam -CH3 =N- -H -Cl -Cl 
1,4-Benzodiazepines R1 R2 R3 R2’ R8 
7-Amino-flunitrazepam (metabolite) -CH3 =O -H -F -NH2 
Chlordiazepoxide ----- -NHCH3 -H -H -Cl 
Clonazepam -H =O -H -Cl -NO2 
Diazepam -CH3 =O -H -H -Cl 
Flunitrazepam -CH3 =O -H -F -NO2 
Lorazepam -H =O -OH -Cl -Cl 
Nordiazepam (metabolite) -H =O -H -H -Cl 
Oxazepam (metabolite) -H =O -OH -H -Cl 
Table 2: R groups for eleven benzodiazepines on base structures 
The purpose of this research is to demonstrate proof of concept of SERS as a 
sensitive analytical technique for the detection and identification of trace quantities of 
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benzodiazepines in aqueous solutions, which can then be adapted for trace detection in 
toxicological samples.  Gold colloidal solutions were used in this study because they 
were found to provide signal enhancement for all of the benzodiazepines examined in this 
study.  The sensitivity of the technique was optimized by examining the parameters for 
the SERS detection, including the aggregating agent, its counter ion and its concentration.   
4.3 Experimental 
 DEA-exempt, Cerrilliant benzodiazepine solutions (alprazolam LOT# FE110211-
01, chlordiazepoxide LOT# FE062310-01, clonazepam LOT# FE032311-03, diazepam 
LOT# FE082310-03, flunitrazepam LOT# FE080311-01, lorazepam LOT# FE032511-
01, midazolam LOT# FE100110-01, nordiazepam LOT# FE110410-01, oxazepam LOT# 
FE111710-02, triazolam LOT# FE122110-03) and Lipomed benzodiazepine solution (7-
amino-flunitrazepam LOT# 74.1B2.1L2) were obtained from Fisher Scientific.  These 
samples were solutions in methanol with a concentration of 1 mg/mL.  Standards were 
dried down under nitrogen and then rediluted to 250 μg/mL in 10% methanol.  These 
stock solutions were then used to prepare stock standards in 10% methanol ranging in 
concentration from 50 ng/mL to 100 μg/mL.  
 Gold colloids were prepared following the modified method of Lee and Meisel 
proposed by Cyrankieqicz39, 36 using the reduction of hydrogen tetrachloroaurate (Acros 
Organics LOT# A0315355) with a 1% sodium citrate (EM Science LOT# 126409-
120694) solution.  Nanoparticles were characterized by measuring ultraviolet-visible 
absorbance (Varian Cary 100 Bio UV-visible spectrophotometer) as well as physically 
measuring particle size using scanning electron microscopy (JEOL JSM 5900LV, 3.0 nm 
resolution). The following solutions of different aggregating agents were prepared at the 
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following concentrations: 3.34 M, 1.67 M, and 0.84 M of MgCl2, and 1.67 M of CaCl2, 
KCl, and NaCl.  All solutions were prepared with ultrapure water.  Glassware was 
cleaned with detergent followed by deionized water and then methanol.   
 Urine was spiked with 7-amino-flunitrazepam, diazepam, and nordiazepam at 
concentrations ranging from of 25 ng/mL to 500 ng/mL (IRB-13-0035). Liquid-liquid 
extraction was performed as follows:  1 mL spiked urine was mixed with 100 μL of 100 
mM buffered phosphate at pH of 6.  This was extracted in 0.5 mL of ethyl acetate.  100 
μL of 1 M NaOH was then added to the aqueous phase and extracted again with 0.5 mL 
of ethyl acetate.  The organic phases were dried down and reconstituted in 100 μL of 10% 
methanol. 
 For SERS experiments 980 μL of gold colloids were placed in sample vial 
followed by 10 μL of the aggregating agent.  This was vortexed for 30 seconds.  10 μL of 
drug sample solution was then added and vortexed for 30 seconds.36  
 SERS spectra were obtained with a Perkin Elmer Raman Station 400F with 785 
nm excitation for four spectral scans each at a 10 second exposure.  The power at the 
sample surface was 100 mW.  Samples were transferred to SERS inactive quartz cuvettes 
for analysis.   
4.4 Results and Discussion 
4.4.1 Nanoparticle Characterization 
The gold nanoparticles produced using the modified Lee Meisel method were 
dark red in color with an absorbance maximum of 522 nm (Fig. 23).  This is consistent 
with a particle size of approximately 30 nm.  This particle size was confirmed further 
through the use of a scanning electron microscope. 
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Figure 23: UV-Visible spectra of gold nanoparticles, 30 nm particles 
4.4.2 Comparison of Different Aggregating Agents 
Four aggregating agents, MgCl2, CaCl2, KCl, and NaCl were compared to 
optimize the detection of all eleven benzodiazepines.  The optimum aggregating agent 
should provide detection of all compounds at the lowest possible concentration as well as 
producing a linear response.   Furthermore since our goal was to achieve ultra-trace 
detection for application in drug facilitated sexual assault, we targeted a limit of detection 
of 50 ng/mL or lower.   An initial stock concentration of 1.67 M was used for all four 
agents and diluted as necessary.  The initial color of the gold nanoparticles was a dark red 
and following aggregation the solution color varied from dark purple to a colorless 
solution with gray particles that were visible to the naked eye.   
 Fig. 24 shows the SERS spectra of all 11 benzodiazepines from 1800 to 400 cm-1 
using MgCl2 aggregation at 1.67 M.  It was found that for all drugs tested, the resulting 
SERS spectra was did not change with aggregating agent.  These results indicate that all 
four of the aggregate solutions were producing similar interactions at the interface 
between the nanoparticle and drug.   This was important because in order to develop 
consistent calibration curves, a single high intensity peak was used for each drug.  
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Throughout these experiments, all eleven compounds produced unique SERS spectra, 
facilitating the visual identification of each compound.   As noted in Fig. 22 and Table 2, 
the structures of these compounds are very similar, in some cases having a difference of a 
single functional group.  For example, the only structural difference between 
flunitrazepam and 7-amino-flunitrazepam is that the amino group on the R8 location of 
flunitrazepam is reduced to an amine group.  This produces the different SERS spectra 
illustrated in Fig. 24.  The ability to identify these compounds by their spectral 
differences can be of great value in an initial drug screen. 
Calibration curves were created for each benzodiazepine with each aggregating 
agent using the spectral peaks indicated in Fig. 24.  Linear dynamic ranges were reported 
and limits of detection were calculated from calibration curves for all eleven 
benzodiazepines (Table 3).  The sensitivity enhancement produced by the different 
aggregates varied with each specific drug.   
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Figure 24: SERS spectra at 250 ng/mL with MgCl2 (1.67M) aggregation; indicated peaks 
were used for calibration curves 
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Drug Aggregate
Dynamic 
Range 
(ng/mL) R-squared
Standard 
Deviation 
of Blank Slope 
LOD  
3xSD/Slope
ng/mL 
Alprazolam 
MgCl2 2.5 – 50 0.9843 33 29.9 3.3
CaCl2 25 – 100 0.9869 63 12.5 15
KCl 50 – 500 0.9450 140 4.40 97
NaCl 50 – 500 0.9628 57 2.17 79
7-Amino-
Flunitrazepam 
MgCl2 1 – 25 0.8143 260 1710 0.5
CaCl2 1 – 25 0.9772 1700 617 8.1
KCl 50 – 250 0.9580 88 98.0 2.7
NaCl 25 – 500 0.8704 1000 15.3 200
Chlordiazepoxide 
HCl 
MgCl2 100 – 1000 0.9860 790 18.5 130
NaCl 50 – 1000 0.8796 420 2.15 590
Clonazepam MgCl2 100 – 500 0.8252 280 18.9 44KCl 100 – 1000 0.7412 140 19.3 22
Diazepam 
MgCl2 2.5 – 25 0.9936 130 205 1.9
CaCl2 2.5 – 25 0.9023 230 182 3.7
KCl 50 – 500 0.8742 122 17.6 21
NaCl 25 – 1000 0.9360 370 5.71 190
Flunitrazepam 
MgCl2 250 – 2500 0.9138 310 7.70 120
CaCl2 250 – 2500 0.9191 33 6.51 15
NaCl 100 – 2500 0.8043 100 0.572 520
Lorazepam 
MgCl2 250 – 1000 0.9429 93 5.72 49
CaCl2 50 – 1000 0.9872 9.0 2.75 9.8
KCl 250 – 1000 0.9794 100 7.59 40
Oxazepam 
MgCl2 25 – 500 0.9702 120 8.10 45
CaCl2 100 – 1000 0.9765 220 6.43 100
NaCl 50 – 1000 0.9916 310 2.01 470
Nordiazepam 
MgCl2 5 – 50 0.9972 110 97.1 3.3
CaCl2 25 – 100 0.9216 480 9.62 150
NaCl 50 – 500 0.8496 230 1.26 540
Triazolam 
MgCl2 2.5 – 50 0.9574 73 62.6 3.5
CaCl2 5 – 100 0.9239 90 33.8 8.0
KCl 25 – 100 0.9602 400 47.3 26
NaCl 25 – 250 0.9413 200 18.1 34
Midazolam 
MgCl2 10 – 100 0.8902 18 18.7 2.9
CaCl2 25 – 100 0.9271 140 15.3 27
KCl 50 – 500 0.7633 140 0.809 530
Table 3: Figures of Merit 
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KCl aggregation at 1.67 M provided spectra for only seven of the eleven 
compounds within the concentration range tested (1-1000 ng/mL).  For these seven drugs 
the limits of detection ranged from 25 to 250 ng/mL.   NaCl provided spectra for eight of 
the eleven compounds within the concentration range tested with limits of detection 
ranging from 25 to 100 ng/mL.  CaCl2 provided spectra for nine of the eleven drugs 
tested.  The limits of detection for this aggregating agent ranged from 1 to 250 ng/mL.  
All three of these aggregating agents produced spectra for some of the benzodiazepines 
tested within 50 ng/mL, however, a more universal aggregation agent was needed to 
permit detection all the analytes of interest.  MgCl2 provided this result.  Not only is it 
shown to produce the lowest limits of detection overall (0.5 – 250 ng/mL), it also 
produced identifying spectra for all eleven analytes of interest within the concentration 
range tested.   
Generalizations can be made about the different effects of these aggregates.  The 
more chlorine ions present, the higher the signal enhancement observed.  In general, 
MgCl2 and CaCl2 provided higher signal intensities for the same drug at the same 
concentration when compared with NaCl and KCl.  This can be observed in Fig. 25.  
Shown are calibration curves for alprazolam using MgCl2 and NaCl as aggregating 
agents.  At 50 ng/mL of alprazolam, a higher signal intensity is observed for MgCl2 than 
for NaCl. This has been reported in the literature25 to be due to the chloride ion effect.  
Sodium citrate is used as a reducing agent to form the gold nanoparticles as well as 
stabilize their formation.   Aggregation results when the chlorine ions displace the citrate 
stabilizer causing particle interactions with the resultant Raman enhancement.  This 
presence of the aggregating agent also facilitates an increase in the signal intensity by 
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affecting the ionic strength of the surrounding solution and the surface charge of the 
substrate.64    
 
Figure 25: Comparison of MgCl2 and NaCl aggregation for alprazolam detection 
It was also noted that the cation may contribute to the enhancement as well.  
MgCl2 and KCl provided higher intensity signals when compared to CaCl2 and NaCl, 
respectively.   This can be observed in Fig. 26.  Shown are calibration curves for 
alprazolam using MgCl2 and CaCl2 as aggregating agents.  At 25 ng/mL of alprazolam a 
higher signal intensity is observed for MgCl2 than for CaCl2.   This effect has been noted 
in the literature37 and may be due to the size of the cation; however is not as well studied 
as the effect of anions on the SERS signal.  Smaller cations facilitated the nanoparticles 
to move closer together, increasing the likelihood of hotspot formation, increasing signal 
intensity.  MgCl2 was shown to produce the lowest limits of detection both observable (1 
– 250 ng/mL) as well as calculated (0.5 – 100 ng/mL) across the range of drugs.  
Therefore, MgCl2 was the optimum aggregating agent universally, so it was optimized.   
69 
   
 
Figure 26: Comparison of MgCl2 and CaCl2 aggregation for alprazolam detection 
4.4.3 MgCl2 Concentration Optimization 
In order to further optimize the detection system, various concentrations (3.34 M, 
1.67 M and 0.84M) of MgCl2, were tested to determine if increasing or decreasing the 
concentration of the agent would affect the SERS signal.  For each of the eleven 
benzodiazepines, the lowest observable concentration obtained in the first part of this 
study was used.  Fig. 27 shows the Raman signal intensity observed for each drug at all 
three MgCl2 concentrations.   
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Figure 27: Comparison of 3 concentrations of MgCl2 aggregating reagent for all eleven 
benzodiazepines at their lowest observable concentration 
Although in some cases, the use of 0.84M MgCl2 (chlordiazepoxide) and 3.34 M 
MgCl2 (oxazepam) produced a higher intensity signal than 1.67 M MgCl2, certain drugs 
produced no signal at these lower concentrations.   For example the use of 0.84 M MgCl2 
produced no signal for triazolam and midazolam and the 3.34 M MgCl2 solution 
produced no signal for alprazolam.  Therefore, 1.67 M MgCl2 was used as the 
aggregating agent in all further studies. 
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4.4.4 Proof of Concept – Spiked Urine Sample 
Although this technique shows low detection limits in aqueous samples, proof of 
concept is necessary to show applicability to cases involving real biological samples.  In 
order to do this, a number of the above samples, including 7-amino-flunitrazepam, 
diazepam, and nordiazepam, were spiked into urine and tested.  For example 7-amino-
flunitrazepam was spiked into a urine sample at a concentration of 250 ng/mL and then 
extracted using the liquid-liquid extraction method described previously in this paper.  
SERS samples were prepared from the 7-amino-flunitrazepam standard and the urine 
extract.   Fig. 28 shows the SERS spectra produced in both cases.   The visual similarity 
of the two spectra is clear, and the high intensity peaks at 1233 cm-1, 1613 cm-1, 1074 cm-
1, and 1352 cm-1peaks can be noted.  Three different benzodiazepines, 7-amino-
flunitrazepam, diazepam, and nordiazepam, were successfully spiked into urine at 
concentrations ranging from 25 ng/mL to 500 ng/mL, extracted by liquid-liquid 
extraction, and detected using the optimized SERS method.  Samples were run in 
triplicate and calibration curves were produced.  All three drugs produced a dynamic 
range from 25 to 500 ng/mL with R2 values between 0.98 and 0.92 and limits of detection 
from 2 ng/mL to 10 ng/mL, which is below our target of 50 ng/mL. These results 
demonstrate that benzodiazepines extracted from urine can be detected using this 
optimized SERS method.   
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Figure 28: SERS spectra of 7-amino-flunitrazepam standard compared to SERS spectra 
of 7-amino-flunitrazepam extract from urine 
4.5 Conclusions 
This paper presents an initial assessment of the application of surface enhanced 
Raman spectroscopy to toxicological samples.   SERS spectra were obtained for eleven 
benzodiazepines of concern in drug facilitated sexual assault.  The technique produces 
enhancement levels several orders of magnitude higher than would be available with 
standard Raman spectroscopy, permitting trace level analysis of drugs in aqueous 
solutions.    Also, this method overcomes the limitations of some currently available 
immunoassay techniques by providing lower detection limits and specific spectral based 
determinations.  The method was stable, producing reproducible SERS intensities and 
frequencies over a wide range of concentrations.   
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For all aggregating agents tested,1.67 M MgCl2 produced the highest signal 
intensities across all eleven drugs with detection limits ranging from 0.5 to 127ng/mL and 
all.  Furthermore, with the exception of chlordiazepoxide and flunitrazepam, detection 
limits below 50ng/mL were achieved for all tested compounds. This work demonstrates 
the importance of properly selecting an aggregation agent for SERS detection in 
suspension. 
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5. SUPPORTED LIQUID EXCTRATION OF BENZODIAZPINES FROM URINE 
5.1 Introduction 
 The detection of illicit drugs in biological matrixes are important in both the 
clinical and forensic setting.  Often, however, the direct analysis of these biological 
matrixes is not possible due to the complexity of the matrix.  Specifically in urine, there 
are a number of salts, creatinine, urea, proteins, and any number of other exogenous 
compounds.  In order to allow for the detection of an illicit drug of interest, pretreatment 
and an extraction technique must be employed in order to remove the analyte while 
leaving behind the rest of the biological matrix.  For benzodiazepines, the most common 
pretreatment method is enzymatic hydrolysis with glucuronidase, a one to two hour 
process, involving the removal of the drug from the glucuronidated conjugate that is 
produced in high quantities during the metabolism process.9,10,12,17  Other pretreatments 
involve dilution of the sample with water or a buffer prior to extraction.  When extracting 
benzodiazepines from urine, the two most common methods employed are solid phase 
extraction (SPE) and liquid-liquid extraction (LLE).   
 Solid phase extraction uses a solid particle, usually a chromatographic packing 
material, contained in a cartridge.  The ability of the analyte to partition between the 
liquid phase and the stationary phase causes the retention or elution of that analyte.  The 
packing material chosen depends on the analyte and whether that analyte is retained or 
eluted from the stationary phase at certain steps along the extraction process.  These 
stationary phases are made up of purified and modified silica.  SPE methods normally 
contains a number of steps: preconditioning the column with an organic, flushing the 
column to remove the organic, loading a buffered biological sample, washing the loaded 
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sample, drying the column, and elution.  For some drugs, benzodiazepines in particular, 
that are highly partitioned from aqueous to organic this extraction can consume more 
solvent, material, and more time, than a simpler extraction method.5  In turn, this costs 
laboratories more money.   
Solid phase extraction has been applied to the extraction of benzodiazepines from 
a number of biological matrixes.65, 66,67,68, 69  Hegstad et. al. used a mixed mode polymer-
bases solid phase extraction column to extract benzodiazepines common in Norway form 
urine samples.  This procedure utilized a two hour enzymatic hydrolysis step prior to 
extraction and involved a four step extraction procedure.  The extraction had a recovery 
range of 51% - 89% at an approximate concentration of 150 μg/mL determined using 
liquid chromatography tandem mass spectroscopy.68   This type of SPE method was taken 
further with the addition of dispersive liquid-liquid microextraction following the SPE 
extraction.69  The dispersive liquid-liquid microextraction utilized the property of 
benzodiazepines high partitioning from water to chloroform.  Post SPE extraction, the 
eluent was reconstituted in water and chloroform was added and droplets were allowed to 
form.  These droplets now contained the benzodiazepines of interest and could be 
removed and injected directly into a gas chromatograph for detection.  It was found that 
the addition of the dispersive liquid-liquid microextraction increased the recoveries 
(92.5% – 110%) compared to methods which just utilized SPE.69  While SPE often has 
good recoveries (>50%) for benzodiazepines, the time and cost involved makes faster 
simplified extraction techniques viable alternatives for screening for benzodiazepines in 
urine.   
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Liquid-liquid extraction typically involves the isolation of an analyte based on its 
ability to partition from one phase into another.  While liquid-liquid extraction (LLE) is a 
rapid, easy technique for removing analytes from a biological matrix, many times the 
analyte of interest is not the only compound which is removed from the biological 
sample.  This poses a problem when using surface-enhanced Raman spectroscopy 
(SERS) as a detection technique.  Interferences, such as other drugs, can be co-extracted 
and interfere with the analyte spectra.  Also, as discussed in Chapter 4, aggregating 
agents, often salts, and their concentrations can have an effect on the SERS signal.  Often 
salts can be co-extracted into the organic phase of the liquid-liquid extraction, and this 
can reduce the SERS signal.  LLE has been shown to be an efficient method for the 
isolation of benzodiazepines from both biological and other liquid matrixes.  The 
McCord research group has performed a number of studies which have utilized liquid-
liquid extraction using a phosphate buffer at a pH of 6 and ethyl acetate to extract 
benzodiazepines from beverages70,71 as well as urine.6,72 Since LLE can be an important 
method for the isolation of interest, a search was made for a method capable of utilizing 
the benefits of LLE (speed, ease of use, low cost) without many of the downsides 
(coextractions of interferences and salts).   
 Supported liquid extraction (SLE) is a cleaner and more efficient extraction 
method than LLE.  It can also provide a sample preparation time of under fifteen minutes.  
SLE uses a solid silica based diatomaceous earth packed into a column.  The use of 
columns permits this method to become automated.  Figure 29 shows the work flow of 
SLE.  The pretreated aqueous biological sample is applied to the top of the column where 
it spreads over the surface of the support and is absorbed onto a dry column.  Unlike solid 
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phase extraction, there are no preconditioning steps and no flow-through, reducing 
sample preparation time and the need for waste containers.73  The pretreatment should 
allowing for the analytes of interest to be present in their neutral form.  Once applied, the 
analytes remain on the surface of the support mimicking the phase interface in LLE.  
When the organic extraction solvent is applied, the analytes are then desorbed and the 
solvent is collected.   
 
Figure 29:  Work flow of supported liquid extraction73 
 Supported liquid extraction has previous been applied to the extraction of 
benzodiazepines from urine prior to high-performance liquid chromatography74 and ultra-
pressure liquid chromatography followed by tandem mass spectrometry.75  Both studies 
employed a high pH buffer as a sample preparation step, 9 and 11 respectively.74, 75  
Unfortunately in addition to permitting complete extraction of all benzodiazepines, this 
procedure will also extract other basic drugs with high pKas.  This interference is not a 
problem when chromatographic methods are used, but when screening for 
benzodiazepines using (SERS) the number of Raman active interferences needs to be 
limited.  Table 4 lists the eleven benzodiazepines which were tested in this study along 
with their relevant with pKa values.  The ionization percentages were also calculated 
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using an acetate buffer at a pH of five.  After calculations, it was shown that at a pH of 
5.0 all but one of the benzodiazepines of interest in this study, midazolam, have a low 
percentage of ionization which is ideal for SLE as for optimum extraction of all analytes 
should be extracted in their neutral state.  This low pH will also allow for the removal of 
many possible interferences, such a codeine, that have high pKa values.  Percent 
ionizations were calculated using a simplified version of the Henderson Hasselback 
equation and a using an acetate buffer at a pH of five.  Equation 9 was used for 
calculating the percent ionization of the basic pKa, which is the deprotonation of the 
cationic form of the N-4 on the diazepine ring.  Equation 10 was used for calculating the 
percent ionization of the acidic pKa due to the deprotonation of the N-1 on the diazepine 
ring to produce an anionic species.26, 25  
%	݅݋݊݅ݖ݁݀	ܾܽݏ݅ܿ ൌ 	 ଵ଴଴ଵା	ଵ଴ሺ೛ಹష೛಼ೌሻ                                                        (9) 
%	݅݋݊݅ݖ݁݀	ܽܿ݅݀݅ܿ ൌ 	 ଵ଴଴ଵା	ଵ଴ሺ೛಼ೌష೛ಹሻ                                                       (10) 
 
Table 4: pKa and ionization data on eleven benzodiazepines 
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5.2 Experimental 
All solutions were prepared with ultrapure water.  Glassware was cleaned with 
detergent followed by deionized water and then methanol.  All chemicals not directly 
listed were purchased from Fisher Scientific.  DEA-exempt, Cerrilliant benzodiazepine 
solutions (alprazolam LOT# FE110211-01, chlordiazepoxide LOT# FE062310-01, 
clonazepam LOT# FE032311-03, diazepam LOT# FE082310-03, flunitrazepam LOT# 
FE080311-01, lorazepam LOT# FE032511-01, midazolam LOT# FE100110-01, 
nordiazepam LOT# FE110410-01, oxazepam LOT# FE111710-02, triazolam LOT# 
FE122110-03) and Lipomed benzodiazepine solution (7-amino-flunitrazepam LOT# 
74.1B2.1L2) were obtained from Fisher Scientific.  These samples were solutions in 
methanol with a concentration of 1 mg/mL.  Urine was spiked with drug standards at 
concentrations ranging from of 6 ng/mL to 25,000 ng/mL (IRB-13-0035). 
Isolute® SLE+ supported liquid extraction 2 mL and 5 mL capacity extraction 
columns were obtained from Biotage.  For the 2 mL extraction columns three different 
sample preparations methods were used on 1 mL spiked urine sample.  Dilution 1:1 with 
deionized water (pH = 6.5), dilution 1:1 with 100 mM ammonium acetate (NH4OAc) 
buffer adjusted to pH 5.0 with 1% formic acid, and dilution with 950 μL of 100 mM 
NH4OAc buffer adjusted to pH 5.0 and 50 μL β-glucuronidase at 4500 U/mL with 
hydrolysis in water bath at 60˚C for two hours.73 For the 5 mL extraction columns 2.5 mL 
of urine spiked with alprazolam was diluted 1:1 with 100 mM NH4OAc.   
The supported liquid extraction was performed as follows for the 2 mL extraction 
columns: loaded 2 mL of pretreated sample onto column with pulsed vacuum to initiate 
flow, leave for 5 minutes. Two and a half mL of dichloromethane was applied and 
80 
   
allowed to flow under gravity for 5 minutes, this was repeated a second time and vacuum 
was then applied to elute.  Samples were then dried under nitrogen and reconstituted in 
100 μL of 10% methanol.  Each extraction was performed in triplicate.  The procedure 
was similar for the 5 mL columns however samples were loaded with 5 mL of pretreated 
sample and aliquots of extraction solvent were increased to a volume of 5 mL 
dichloromethane.  
The optimized SERS method and sample preparation using gold colloids and 1.67 
M MgCl2 previously discussed was used to detect the drugs following extraction for this 
study.6  SERS spectra were obtained with a Perkin Elmer Raman Station 400F with 785 
nm excitation for four spectral scans each at a 10 second exposure.  The power at the 
sample surface was 100 mW.  Samples were transferred to SERS inactive quartz cuvettes 
for analysis.   
5.3 Results and Discussion 
5.3.1 Comparison of sample preparation  
 Three different sample preparation methods were tested in order to determine 
which would extract all eleven benzodiazepines in this study.  As discussed in the 
methods these were dilution of urine sample with water, dilution of urine sample with 
acetate buffer at a pH of 5.0, and dilution of urine sample with acetate buffer at a pH of 
5.0 followed by enzyme hydrolysis.  Dilution with water was chosen due to the simplicity 
of the method.  The acetate buffer sample preparation was chosen in order to have more 
control of the pH (5.0) and ionization of the benzodiazepines in the sample.  Finally, 
enzyme hydrolysis was also tested in order to determine if extraction could be improved 
by removing the glucuronide conjugates, allowing for more free-drug to be detected.  For 
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each sample preparation technique, 1 mL of urine spiked with maximum concentrations 
of each benzodiazepine (500 – 25,000 ng/mL) was used.  Figure 30 shows a comparison 
of the Raman intensities produced for one of the benzodiazepines, 7-amino-
flunitrazepam, at 250 ng/mL in urine comparing the three SLE sample preparation 
techniques as well as compared to signal produced from liquid-liquid extraction 
previously published.6   
 
Figure 30: SERS signals for 250 ng/mL 7-amino-flunitrazepam extracted with three SLE 
preparation techniques and liquid-liquid extraction;  All three SLE extractions (A,B,C) 
produced higher Raman intensities (increased extraction) when compared to the liquid-
liquid extraction (D) performed in Chapter 4.  Dilution with water was the most efficient 
extraction in the case of this drug while enzyme hydrolysis was the least efficient.   
 All the SLE preparation techniques provided higher signal intensities than with 
the previously published liquid-liquid extraction method.  It was found that when the 
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spiked urine was diluted 1:1 with deionized water, while having the highest signal 
intensities for some of the benzodiazepines which were efficiently extracted, only 8 of the 
eleven benzodiazepines extracted.  Also four of those that did extract only had very low 
intensity spectral peaks at maximum concentrations (500 – 25,000 ng/mL) which are well 
above the required 50 ng/mL limit.   
 Hydrolysis by β-glucuronidase provided the lowest signal intensities of the three 
preparation techniques.  Hydrolysis provided similar results to dilution with deionized 
water in the number of benzodiazepines which efficiently extracted, eight.  The three 
benzodiazepines which were not detectable by SERS post-extraction were alprazolam, 
midazolam, and triazolam.  Another issue with hydrolysis deals with the potential 
conversion of flunitrazepam to 7-amino-flunitrazepam.  In Figure 31, the SERS spectra 
following hydrolysis and extraction for these two compounds is shown as well as a 
comparison to the SERS spectra of a pure flunitrazepam sample.  The effect of 
conversion is preventing the identification of flunitrazepam as the drug present.  Finally, 
this procedure adds an additional hour to analysis time.  The goal of this project is to 
reduce the total analysis time necessary for the screening of these types of drugs.   
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Figure 31: SERS spectra of (A) flunitrazepam and (B) 7-amino-flunitrazepam using 
hydrolysis sample preparation; compared to SERS spectra of pure (C) flunitrazepam 
 Dilution with ammonium acetate buffer at a pH = 5.0 allowed for extraction of all 
the benzodiazepines in this study.  This preparation technique also provided signal 
intensities greater than those of standard liquid-liquid extraction and the hydrolysis 
preparation.  In addition to a pH of 5.0, the pH of the buffer was also adjusted to 4 and 6 
and extraction performed.  Neither other pH improved the signal observed for the 
benzodiazepines, therefore they did not improve the extraction, thus a pH of 5.0 was 
determined to be optimum.  Dilution with the ammonium acetate buffer at a pH of 5.0 
was chosen as the optimum preparation for SLE and was used to produce calibration 
curves and determine limits of detection for this technique.   
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5.3.2 Figures of Merit 
 Calibration curves were created for each benzodiazepine following extraction of 1 
mL of spiked urine using the spectral peaks indicated in Table 5.  Linear dynamic ranges 
were reported and limits of detection were calculated from calibration curves for all 
eleven benzodiazepines (Table 2).  This limits of detection were compared to those of the 
pure drug standards determined in Chapter 4.6   
 
Table 5: Figures of Merit; note the higher limits of detection for the extracted drugs when 
compared to the pure drugs.   
 Overall, it was found that limits of detection for all the benzodiazepines studied 
except for the 1,2-triazolo and 1,2-imdazo benzodiazepines, was similar, though still 
slightly higher that that determined for the pure samples.  Due to no extraction system 
being one hundred percent efficient, the limits of detection post-extraction are expected 
to be slightly higher than those of the pure drug.  For the two classes of drugs that did not 
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produce similar limits of detection between the extracted and pure drug, the 1,2-triazolo 
and 1,2-imdazo benzodiazepines, the pure drugs had limits of detection between 2.9 
ng/mL and 3.3 ng/mL, the extracted drug had limits of detection at 240 and 600 ng/mL 
respectively.  This concentration is ten times the required maximum limit of detection for 
drug facilitated sexual assault cases. Components of urine, such as urea and creatinine 
were examined for their interference with the extraction of these three benzodiazepines 
and were found to not interfere.  It was determined that these three benzodiazepines, 
alprazolam, midazolam and triazolam, were not extracting efficiently.  These three 
compounds are the only benzodiazepines used in this study that contain an additional 1,3-
diazole ring or 1,2,4-triazole linked to the 1-2 bond of the 1,4-diazepine ring 
benzodiazepine base structure.  The additional nitrogens, when compared to the other 
benzodiazepines in this study, could be having an effect on the extraction of these drugs.  
Another important note is specifically for midazolam, which has a pKa of 6.  Table 4 
shows that when the percent ionization is calculated for midazolam under the conditions 
of the acetate buffer (pH = 5.0) used in these experiments, it is 94% ionized.  Due the 
extraction technique occurring efficiently with the neutral analyte, this high percent 
ionization for midazolam greatly reduces the efficiency of the extraction.  However, if the 
pH of the buffer was to be increased, while the percent of ionization would go down, this 
would also increase the likelihood of other basic drugs being extracted with the 
benzodiazepines.  A number of experiments were performed in an attempt to improve 
recovery of these compounds in urine. 
 The amount of urine extracted in the SLE extraction columns was increased from 
1 mL to 2.5 mL of urine.  In order to do this, the size of the extraction cartridge was 
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increased from 2 mL to 5 mL.  Samples of alprazolam were spiked into the urine ranging 
in concentration from 100 – 25000 ng/mL following the extraction procedure in the 
methods for the 5 mL SLE cartridges.  This concentration range is the same as for the 1 
mL urine samples.  Samples were then analyzed using the optimized SERS method 
previously mentioned.  It was found that the detection limits did not improve for 
alprazolam and the noise in the spectrum was increased.   
 In order to ascertain if extraction efficiency was an issue with alprazolam in 
particular, infusion mass spectrometry was performed.  A spiked urine sample of 
alprazolam was prepared at 250 ng/mL and extracted using the optimized 2 mL SLE 
cartridge method and standards were prepared at a corresponding 100% extraction 
concentration.  A Waters Quattro Micro API instrument was used with the following set 
parameters: capillary voltage (2.89 kV), cone voltage (45 V), extractor voltage (3 V), 
source temperature (125˚C), desolvation temperature (400˚C).  The sample was injected 
at a rate of 25 μL/min with a spectral acquisition time of one second.  The instrument was 
flushed between samples with methanol.  Using peak area it was found that alprazolam 
was only 6% extracted when compared to the amount extracted from a pure sample (no 
urine).  Therefore, a more specific extraction technique needs to be employed for some of 
the benzodiazepines, specifically the 1,2-triazolo and 1,2-imdazo benzodiazepines.   
5.4 Conclusions 
 Supported liquid extraction coupled with surface enhanced Raman spectroscopy 
has been shown to provide a rapid (less than twenty minutes) and less complicated 
method of screening for benzodiazepines in urine at concentrations relevant to drug 
facilitated sexual assault cases.  The detection limits range from 6 – 640 ng/mL for the 
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benzodiazepines in this study.  Other extraction techniques may need to be examined in 
order to further improve the detection limits for some benzodiazepines, specifically the 
1,2-triazolo and 1,2-imdazo benzodiazepines.  This technique also has the added benefit 
of providing spectral information about the compound detected giving investigators 
information about the specific compound rather than just the class of drugs.   
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6. INTERFERENCE STUDY OF COMMOMLY ENCOUNTERED DRUGS 
FOUND IN DRUG FACILITATED SEXUAL ASSAULT SAMPLES 
6.1 Introduction 
 While the overall goal of these studies is to optimize the extraction of 
benzodiazepines from simulated drug facilitated sexual assault sample, consideration 
needs to be given to other drugs that are commonly present in a urine sample for these 
cases.  Many times victims of such crimes may not have ingested just the criminally 
administered drug but other compounds such as over the counter medication, 
acetaminophen, a cup of coffee, caffeine, or prescription medications, such as codeine.10-
11 It is important to determine whether these other common compounds found in 
toxicological urine samples interfere with either the optimized surface enhanced Raman 
technique or with the optimized extraction method.   
 A range of drugs was examined from common over the counter medication, such 
as acetaminophen and salicylic acid, to illegal drugs such as gammahydroxy buteric acid.  
Table 6 lists the interference compounds to be examined, the concentration ranges 
commonly encountered in urine as well each the compound’s pKa value.  These pKa 
values range from low (2.97 for salicylic acid) to very high (14 for caffeine).  Those 
compounds with low pKa were expected to co-extract with the optimized supported 
liquid extraction (SLE) at a pH of 5.0.  It was also important to examine whether these 
compounds will produce a SERS spectrum using the optimized method.6  For those 
compounds with high pKas, it was expected that at low pH these compounds will be 
retained by the SLE substrate due to being more ionized at the extraction preparation pH 
of 5. 
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Drug Urine Concentration Range pKa 
Caffeine 1 – 15 μg/mL76 14 
Gammahydroxy buteric acid (GHB) 1 – 15 μg/mL77 4.7 
Codeine 2 – 62 μg/mL78 8.2 
Nicotine 0.1 – 3 μg/mL79 8.5 
Cotinine 0.1 – 3 μg/mL79 8.8 
Cocaine 0.05 – 10 μg/mL80 8.6 
Δ9-tetrahydrocannabinol 2.5 – 240 ng/mL81 10.6 
Salicylic acid 0.05 – 3 mg/mL82 2.97 
Acetaminophen 0.005 – 50 μg/mL83 9.5 
 
Table 6: Interference compounds studied with common urine concentration and pKas 
6.2 Experimental 
All solutions were prepared with ultrapure water.  Glassware was cleaned with 
detergent followed by deionized water and then methanol.  All chemicals not directly 
listed were purchased from Fisher Scientific.  DEA-exempt, Cerrilliant drug solutions 
(codeine LOT# FE052011-04, cotinine LOT# FN061710-01, cocaine HCl LOT# 
FE051012-01, gammahydroxy buteric acid (GHB) LOT# b018, and Δ9-
tetrahydrocannabinol  (THC) LOT# FE121112-02), Lipomed benzodiazepine solution (7-
amino-flunitrazepam LOT# 74.1B2.1L2), and Crescent Chemical Co. Inc drug solution 
(nicotine LOT# 04CC115) were obtained from Fisher Scientific.  These samples were 
solutions in methanol with a concentration of 1 mg/mL.  Acetaminophen (Acros LOT # 
A0317675), salicylic acid, and caffeine were powdered compounds obtained from Fisher 
Scientific.   
Drug standard dilutions were prepared in concentration ranges as follows in 10% 
methanol: GHB (10 μg/mL – 150 μg/mL), caffeine (15 μg/mL – 75 μg/mL), codeine (10 
μg/mL – 310 μg/mL), cotinine and nicotine (0.5 μg/mL – 15 μg/mL), salicylic acid (0.05 
mg/mL – 1.5 mg/mL), acetaminophen (0.025 μg/mL – 250 μg/mL), cocaine (0.25 μg/mL 
90 
   
– 50 μg/mL), and THC (10 ng/mL – 1250 ng/mL).  These concentration ranges take into 
account the increase in concentration following extraction to mimic the results of an 
extracted sample.   
Urine was spiked with interference drug standards at the range of concentrations 
reported in Table 6 as well as with 7-amino-flunitrazepam standard at a concentration of 
250 ng/mL (IRB-13-0035).  Isolute® SLE+ supported liquid extraction 2 mL capacity 
extraction columns were obtained from Biotage.  1 mL of spiked urine sample was 
diluted 1:1 with 100 mM ammonium acetate (NH4OAc) buffer adjusted to pH 5.0 with 
1% formic acid.73  The supported liquid extraction was performed as follows: loaded 2 
mL of pretreated sample onto column with pulsed vacuum to initiate flow, leave for 5 
minutes.  2.5 mL of dichloromethane was applied and allowed to flow under gravity for 5 
minutes, this was repeated a second time and vacuum was then applied to elute.  Samples 
were then dried under nitrogen and reconstituted in 100 μL of 10% methanol.  Each 
extraction was performed in triplicate.   
The optimized SERS method and sample preparation using gold colloids and 1.67 
M MgCl2 previously discussed was used to detect the pure drugs as well as following 
extraction for this study.6  SERS spectra were obtained with a Perkin Elmer Raman 
Station 400F with 785 nm excitation for four spectral scans each at a 10 second exposure.  
The power at the sample surface was 100 mW.  Samples were transferred to SERS 
inactive quartz cuvettes for analysis.   
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6.3 Results and Discussion 
6.3.1 Pure interference compounds 
 A range of concentrations of each interferant was tested to see if SERS spectra 
would be produced using the established optimized method.6  This was done to assess 
whether the extraction method for the benzodiazepines was needed to remove these 
compounds and if co-extraction did occur, would these drugs interfere in obtaining the 
spectra of benzodiazepines.  Of the nine most common interferences, caffeine, GHB, 
cocaine, salicylic acid, and acetaminophen did not produce any SERS signal using the 
optimized method and over the biologically relevant concentrations.  Therefore these five 
compounds should not cause interference when present in a urine sample.  The other four 
compounds, nicotine, cotinine, codeine and THC did produce strong SERS signals and 
each will each be discussed in detail.   
 Nicotine and it’s major metabolite cotinine do not produce a spectra containing a 
great number of peaks but both compounds had a high intensity, sharp peak at 1030 cm-1 
(Figure 32).  Calibration curves were prepared using the peak at 1030 cm-1 for intensity 
measurements, over the range of concentrations and it was found that both drugs had 
portions of the curve above the linear range for the detection of these two drugs.    If the 
linear range was established, limits of detection could be determined and this SERS 
method could be used for the detection of nicotine and cotinine. This limit of detection 
would be well below the lowest concentration prepared here (0.5 μg/mL) due to the high 
signal intensities.  Previous work has performed using SERS to detect nicotine which 
used hydroxylamine reduced silver nanoparticles in a polydimethylsiloxane microfluidic 
device to gain detection limits of 0.1 μg/mL.84 Gold nanoparticles may improve this 
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analysis.  Due to the pKa of these compounds (8.5 and 8.8), the optimized supported 
liquid extraction method which occurs at a pH = 5.0, should remove these compounds 
when extracting benzodiazepines.    
 
Figure 32: SERS of nicotine and cotinine, 5 ng/mL each 
 Codeine produced a very strong spectra rich with spectral peaks (Figure 33).  The 
peak at 1430 cm-1 was used to measure intensity to prepare a calibration curve.  It was 
found that all concentrations of codeine prepared were above the linear range of the 
compound, with the highest signal intensity occurring at 10 μg/mL.  By preparing drug 
concentrations below this value, the linear dynamic range can be reached and limits of 
detection using the optimized SERS method for codeine can be established.  Future work 
could adapt this method for the detection of codeine and other opiates, due to their 
structural similarity, in toxicological samples.  Codeine, however, should not affect the 
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detection of benzodiazepines due to the pKa of codeine (8.2) being well about the pH of 
the optimized SLE method (5) and it should be removed through extraction.     
 
Figure 33: SERS of codeine, 100 ng/mL 
Δ9-tetrahydrocannabinol also produced a very strong spectra rich with spectral peaks 
with intensities ten times those of any of the benzodiazepines previously examined 
(Figure 34).  The peak at 1213 cm-1 was used to measure intensity to prepare a calibration 
curve.  All of the concentrations of THC prepared were above the linear range of the 
compound, with the highest signal intensity occurring at 10 ng/mL, therefore limits of 
detection were not determined.  This discovery is promising for the analysis of the 
current problem in forensic science with the detection of the synthetic cannabinoids.  The 
high signal intensities for THC show that the limits of detection for these types of 
compounds using the optimized SERS method developed here will be very low, in the 
sub nanogram or high picogram range.  The pKa of THC is 10.6, well about the pH used 
94 
   
in the optimized extraction method, therefore, the drug should be removed upon 
extraction. 
 
Figure 34: SERS of Δ9-tetrahydrocannabinol, 0.1 ng/mL 
6.3.2 Extraction of 7-amino-flunitrazepam and interference mixtures 
 Spiked urine samples were prepared as four different mixtures all including 7-
amino-flunitrazepam at 250 ng/mL and a number of interference drugs at the highest 
biologically relevant concentration listed in Table 6.  The four mixtures were designed in 
order to identify the interference compound if one did get co-extracted with the 
benzodiazepine of interest.  Each mixture was extracted using the optimized SLE method 
outlined in Chapter 6.2 and SERS analysis was performed on each extract, which were 
run in triplicate.   
The first mixture contained the interference compounds which produced no SERS 
spectra as the pure drug, caffeine, GHB, cocaine, salicylic acid, and acetaminophen.  The 
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second mixture contained nicotine and cotinine due to their similar spectra.  The third and 
fourth mixtures contained codeine and THC respectively.  Figure 35 displays the SERS 
spectra of 250 ng/mL 7-amino-flunitrazepam spiked in urine alone and the extraction 
results of all four mixtures.  It was observed that in all cases the interference compounds 
tested were either removed from the extraction or if they did co-extract (in the case of 
those five compounds which did not produce a SERS spectra of the pure drug) did not 
interfere in the spectra of the benzodiazepine of interest.  This shows that this technique 
can be applied to toxicological urine samples for the extraction, detection, and 
identification of benzodiazepines without concern for common interferences found in 
victims of drug facilitated sexual.   
 
Figure 35: SERS spectra of extraction of interference mixtures as compared to the SERS 
spectra of extracted 7-amino-flunitrazepam 
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6.4 Conclusions 
 Through interference studies it was found that most common drugs that are 
present in drug facilitated assault case samples do not interfere with the supported liquid 
extraction, surface-enhanced Raman detection or identification of benzodiazepines.  It 
was also found that the optimized surface-enhanced Raman detection determined 
previously6 can also be applied for the detection of other forensically important 
compounds such as opiates and synthetic cannabinoids.  Overall this work shows the 
applicability of using this rapid technique, which reduces total analysis time from 
extraction to detection to under twenty minutes, while minimizing (1 mL) the amount of 
biological sample is required without concern for the most common interference 
compounds.   
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7. VIBRATIONAL SPECTRAL ANALYSIS OF ELEVEN BENZOIDAZEPINES 
7.1 Introduction 
Raman spectra arise from the various changes in energy from vibrational and 
electronic transitions of a molecule.  The frequency of vibrations can be determined 
through a quantum treatment, assuming that the transitions in vibrational energy levels 
are brought about by the absorption of radiation, and that the provided energy exactly 
matches the difference in the energy levels (ΔE) between the vibrational quantum states.  
This occurs when the vibration causes a change in the dipole moment.26  Using this 
treatment, the wavenumber of a given bond in a molecule can be calculated to look at the 
expected vibrational frequency for a particular bond in a molecule, see Equation 11.  

k
c2
1             (11) 
Equation 11: where ν is the wavenumber of an absorption maximum (cm-1), k is the force 
constant for the bond (N/m), c is the velocity of light (cm s-1), and μ is the reduced mass 
(kg) defined by Equation 1226 
21
21
mm
mm
           (12) 
Equation 12: Reduced mass calculation26 
It is known that for a given bond, the energy shifts that are observed in a Raman 
experiment can be compared to those observed in an infrared spectroscopic experiment.  
If a bond in the molecule is both Raman and infrared active, it is expected that these 
energies will be identical.  Due to this known infrared spectra can be utilized to determine 
the identity of bands in a Raman spectrum for the same molecule.  Also, compounds with 
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similar structures may have similar spectral peaks that relate to similar bonds in the 
molecule.  Variation in adjacent bonds can cause these energies to shift slightly between 
molecules.   
In order to establish the peak identities for the individual benzodiazepines, the 
SERS spectra produced at a concentration of 250 ng/mL were compared to previously 
published peak assignments for the Raman spectra of certain drugs.61, 44, 85  Neville and 
Shurvell have previously provided peak assignments in the Raman spectra of diazepam as 
well as four other closely related 1,4-benzodiazpines (nordiazepam, pinazepam, 
halazepam, and prazepam) that were not examined in this study.61  Though these 
compounds were not examined here, the peak assignments can be used to relate other 
structurally similar benzodiazepines.  Raman assignments produced by this group for 
other benzodiazepines were also used to provide a comprehensive analysis.60, 62  Peak 
assignments have also been performed by Trachta, et. al. after SERS analysis.44  The 
specifically examined nordiazepam, diazepam, oxazepam, and flunitrazepam, which were 
also used in this study, as well as four other benzodiazepines that will not be examined 
further.44  Raman spectral analysis has also been previously performed on the 1,2-triazolo 
and 1,2-imdazo benzodiazepines.85 
In the following discussion, structures of the compounds can be referenced in 
Figure 36 in combination with Table 7.  Also, the rings of the structures are labeled in 
Figure 36 in accordance to how they will be referenced in the discussion and the peak 
tables.  The strength of the bands (very strong – vs, strong – s, moderate – m, weak – w), 
the presence of stretches (str), vibrations (vibr), as well as deformations will be 
mentioned.    
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Figure 36: Base structures of (A) 1,4-benzodiazepines and (B) 1,2-triazolo- and 1,2-
imidazo benzodiazepines 6 
1,2- Triazolo- and 1,2-imidazo-benzodiazepines R1 X R4 R2’ R8 
Alprazolam -CH3 =N- -H -H -Cl 
Midazolam -CH3 =C- -H -F -Cl 
Triazolam -CH3 =N- -H -Cl -Cl 
1,4-Benzodiazepines R1 R2 R3 R2’ R8 
7-Amino-flunitrazepam (metabolite) -CH3 =O -H -F -NH2 
Chlordiazepoxide ----- -NHCH3 -H -H -Cl 
Clonazepam -H =O -H -Cl -NO2 
Diazepam -CH3 =O -H -H -Cl 
Flunitrazepam -CH3 =O -H -F -NO2 
Lorazepam -H =O -OH -Cl -Cl 
Nordiazepam (metabolite) -H =O -H -H -Cl 
Oxazepam (metabolite) -H =O -OH -H -Cl 
Table 7: R groups of benzodiazepines6  
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7.2 Analysis of Peaks for All Benzodiazepines and Major Subgroups 
There are two major spectral bands and two minor spectral bands that can be 
attributed to most benzodiazepines regardless of class. These bands are consistent with 
the diazepine ring and the interaction between the carbon and nitrogen bonding.  There is 
a strong to very strong peak between 1590 – 1613 cm-1, due to the aromatic stretch of the 
carbon nitrogen double bond.  Shifting of this peak is caused by the proximity of 
constituents at the ortho position of the b-ring, which is in free rotation.  The second band 
is medium to very strong in intensity between 1166 – 1175 cm-1, due to the carbon to 
carbon to nitrogen stretch.  This stretch is also observed by weak bands between 856 – 
889 cm-1.  The final weak peak occurs at approximately 820 cm-1 due to the stretch of the 
bonds on a nitrogen atom between two carbon atoms. Table 8 gives the wavenumbers for 
each individual benzodiazepines examined in this study for these two prominent peaks.    
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Assignment Alprazolam 7-Amino Flunitrazepam Chlordiazepoxide Clonazepam 
Arom C=N str (diazepine ring) 1593 s 1613 vs 1595 s 1606 m sh 
C-C-N str (diazepine ring) 1166 m ---------- 1175 m 1168 m 
C-C-N str (diazepine ring) ---------- 882 w 863 m 889 w 
C-N-C str (diazepine ring) ---------- 820 w ---------- ---------- 
Assignment Diazepam Flunitrazepam Lorazepam Midazolam 
Arom C=N str (diazepine ring) 1593 vs 1594 m 1600 s 1593 vs 
C-C-N str (diazepine ring) 1168 m 1168 m 1172 vs 1166 m 
C-C-N str (diazepine ring) 889 w 885 w 856 w ---------- 
C-N-C str (diazepine ring) 824 w ---------- ---------- 829 w 
Assignment Nordiazepam Oxazepam Triazolam  
Arom C=N str (diazepine ring) 1599 vs 1599 s 1590 vs  
C-C-N str (diazepine ring) 1167 s 1172 s 1169 m  
C-C-N str (diazepine ring) 869 m 856 w ----------  
C-N-C str (diazepine ring) ---------- 823 w ----------  
Table 8: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of all 
benzodiazepines studied 44, 85, 86,61  
The spectral characterization of the benzodiazepines can be further broken down 
not only by class but also by the other substituents on the molecule.  The 1,2 – triazolo 
and imidazo benzodiazepines specifically have spectral peaks due to the presence of the 
additional nitrogen containing ring (N-ring) attached at the 1,2 positions on the diazepine 
ring.  The 1,2-triazolo-benzodiazpines alprazolam and triazolam have two weak to 
medium ring “breathing” peaks at 1257 cm-1 and 1138 cm-1 attributed to the N-ring 
containing three nitrogen atoms.  Midazolam, a 1,2- imidazo-benzodizepine which only 
has two nitrogen atoms in the N-ring, has both a weak peak attributed to ring “breathing” 
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(1137 cm-1) as well as a medium peak at 1305 cm-1 due to the amide III band.  Specific 
wavenumbers are shown in Table 9. 
Assignment Alprazolam Midazolam Triazolam 
Amide III band (N-ring) ---------- 1305 m ---------- 
Ring “breathing” (N-ring) 1256 w ---------- 1258 w 
Ring “breathing” (N-ring) 1137 m 1137 w 1139 w 
Table 9: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of 1,2-
triazolo and imidazo benzodiazepines studied85  
The benzene ring in the base benzodiazepine structure indicated as the b-ring in 
Figure 36 can be monosubstituted disubstituted at the ortho position.  While the 
disubstitution shows spectral bands in the infrared spectra,61, 44, 85, 86 these bands are not 
prevalent in the Raman spectra.  Generally, two spectral peaks are observed, however, 
that can be attributed to the monosubstituted b-ring.  There is a peak due to the vibration 
of the benzene ring with the carbon of the diazepine ring at 1205 cm-1 as well as a 
medium peak assigned to the monosubstituted ring “breathing” at approximately 998 cm-
1.  The benzodiazepines which have the monosubstituted b-ring as well as their specific 
wavenumber assignments are in Table 10.  
Assignment Alprazolam Chlordiazepoxide Diazepam Nordiazepam Oxazepam 
C6H5-C vibr.  1207 m ---------- 1207 w 1204 m ---------- 
Monosubstituted 
“breathing” 1001 m 1001 m 996 m 993 m 996 m 
Table 10: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of 
monosubstituted benzene b-ring 
Shared spectral characteristics can also be observed across the benzodiazepines 
based on single structural features.  These bands can help in further classifying the 
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benzodiazepines based on structural similarities.  A weak (alprazolam) to very strong 
(flunitrazepam) peak between 1344-1402 cm-1 is observed in five of the benzodiazepines 
studied due to the stretch of the bond between the nitrogen in the diazepine ring and a 
methyl group.  Six benzodiazepines display a weak peak at approximately 671 cm-1 due 
to the deformation of the carbon oxygen double bond on the diazepine ring.   
Wavenumber Benzodiazepine 
1378 w Alprazolam 
1371 m 7-Amino-Flunitrazepam 
1378 m Chlordiazepoxide 
1404 m Diazepam 
1344 vs Flunitrazepam 
Table 11: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of N-
CH3 stretch 
Wavenumber Benzodiazepine 
670 w 7-Amino-Flunitrazepam 
676 w Clonazepam 
689 m Diazepam 
670 w Flunitrazepam 
671 w Lorazepam 
671 w Nordiazepam 
Table 12: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of C=O 
deformation on diazepine ring 
 
Many benzodiazepines have halogen atoms added to their structure in order to 
improve their physiological activity.  Halogens bonded to carbon atoms show specific 
spectral peaks.  Those benzodiazepines that have chlorine atoms, regardless of being 
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attached on the b,a, or both benzene rings, show a weak spectral band at approximately 
590 cm-1.  Those that have a fluorine atom show a medium to strong spectral band at 
approximately 1220 cm-1.  These halogen bands are generally weak and can be dwarfed 
by other components of the spectra or are so weak they are not above the baseline of the 
spectra.  The later occurs in the cases of where chlorine atoms are present in the molecule 
but no peak is observed (clonazepam, lorazepam, oxazepam).86  The former occurs for 
flunitrazepam, where the broad band at 1344 cm-1, masks any possible peak at 1220 cm-1 
due to the fluorine carbon stretch. 
Wavenumber Benzodiazepine 
589 w Alprazolam 
573 w Chlordiazepoxide 
------* Clonazepam 
593 w Diazepam 
------* Lorazepam 
590 w Midazolam 
------* Oxazepam 
587 w Nordiazepam 
590 w Triazolam 
Table 13: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of C-Cl 
stretching 
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Wavenumber Benzodiazepine 
1233 s 7-Amino-Flunitrazepam 
------- * Flunitrazepam 
1211 m Midazolam 
Table 14: Observed wavenumbers (cm-1) in the surface enhanced Raman Spectra of C-F 
stretching 
7.3 Additional Spectral Analysis of Individual Benzodiazepines 
Each benzodiazepine can be characterized by the individualizing combination of 
peaks previously mentioned as well as additional peaks observed in the following tables.  
The relative intensity of these peaks in relation to the other peaks in the spectra as well as 
their wavenumbers produce a spectral fingerprint for each benzodiazepine.  The 
following pages will show the surface enhanced Raman spectra of each benzodiazepine 
as well as a table outlining the wavenumbers, relative intensities, and assignments for 
each spectral peak.  Strong identifying peaks that were not previously characterized will 
also be discussed in the case of some compounds. 
7.3.1 Alprazolam 
Alprazolam is the most basic of the 1,2-triazolo-benzodiazpines.  There are no 
additional identifying peaks. 
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Figure 37: SERS spectra alprazolam 
Wavenumber Assignment Wavenumber Assignment 
1593 s Arom C=N str (diazepine ring) 1166 m C-C-N str (diazepine ring) 
1559 s Arom C=C str (a-ring) 1137 m Ring breathing (N-ring) 
1485 m Arom C=C str (a-ring) 1001 m Monosubstituted “breathing” (b-ring) 
1378 w CH3 str (N-ring) 927 m CH deformation 
1313 m C=N-C sym. str (diazepine ring) 783 w Ring vibration (b-ring) 
1273 w In plane CH def (a-ring) 708 w ----------------------- 
1256 w Ring “breathing” 689 w Out-of-plane CH deformation (b-ring) 
1207 m C6H5-C vibr. (b-ring) 589 w C-Cl str (a-ring) 
Table 15: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of 
alprazolam85 
 
7.3.2 7-Amino-flunitrazepam 
 7-Amino-flunitrazepam is the major metabolite of flunitrazepam.  An important 
additional identifying peak is the asymmetric NH2 stretch at 1571 cm-1. 
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Figure 38: SERS spectra 7-amino-flunitrazepam 
Wavenumber Assignment Wavenumber Assignment 
1613 vs Arom C=N str (diazepine ring) 924 w C-H deformation 
1571 m Asymmetric NH2 str 882 w C-C-N str (diazepine ring) 
1441 w Arom C=C str (a-ring) 820 w C-N-C str (diazepine ring) 
1426 w Asymmetric CH3 deformation 769 m sh ----------------------- 
1371 m N - CH3 str (diazepine ring) 756 m C-H out of plane deformation 
1335 m sh C-C in plane def (a-, diazepine 
rings) 
733 w ----------------------- 
1289 m In plane CH def (a-ring) 695 w Out-of-plane CH deformation (b-ring) 
1233 s C-F str (b-ring) 670 w C=O deformation 
1130 m C-H in plane deformations (a-, 
diazepine ring) 
638 w Out-of-plane deformation 
1070 s C-H deformation 599 w Ring “breathing” (a,b rings) 
Table 16: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of 7-
amino-flunitrazepam85-86, 61, 44 
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7.3.3 Chlordiazepoxide 
Chlordiazepoxide was the first benzodiazepine synthesized and falls into the 1,4-
benzodiazepine class.  Aside from previously mentioned peaks, the combination of strong 
peaks at 1595, 1544, and 1481 cm-1 is characteristic of this compound. 
 
Figure 39: SERS spectra chlordiazepoxide 
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Wavenumber Assignment Wavenumber Assignment 
1595 s Arom C=N str (diazepine ring) 1155 m ----------------------- 
1544 vs Arom C=C str (a-ring) 1100 w C-H in plane deformation (a, diazepine 
rings) 
1481 s Arom C=C str (a-ring) 1029 w C-H in plane deformation (b-ring) 
1428 m sh Asymmetric CH3 deformation 1001 m Monosubstituted “breathing” (b-ring) 
1412 s ----------------------- 974 w sh ----------------------- 
1378 m N -CH3 str (diazepine ring) 921 w C-H deformation 
1356  ----------------------- 863 m C-C-N str (diazepine ring) 
1318 s C=N-C sym. str (diazepine ring) 716 w ----------------------- 
1270 w C-H in plane deformation (a-
ring) 
680 w Out-of-plane deformation 
1175 m C-C-N str (diazepine ring) 573 w C-Cl str (a-ring) 
Table 17: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of 
chlordiazepoxide44, 61  
7.3.4 Clonazepam 
Clonazepam is a 1,4-benzodiazpine that has two additional peaks which 
correspond to the amino group on the diazepine ring.  These peaks include a medium 
intensity peak at 1569 cm-1 corresponding to the asymmetric NO2 stretch and a weak 
peak at 560 cm-1 due to the deformation of the functional group. 
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Figure 40: SERS spectra clonazepam 
Wavenumber Assignment Wavenumber Assignment 
1606 m sh Arom C=N str (diazepine ring) 1105 w C-H in plane deformation (a, diazepine 
rings)
1569 m Asymmetric NO2 str 1027 w C-H in plane deformation (b-ring) 
1480 w C-H in plane deformation (a-
ring) 
956 w C-H in plane deformation (b-ring) 
1315 vs C=N-C sym. str (diazepine ring) 889 w C-C-N str (diazepine ring) 
1259 w Arom C=C str 772 w C-H out of plane deformation 
1237 w CH2 wag 757 w C-H out of plane deformation 
1205 w C-H in plane deformation (a-
ring) 
676 w C=O deformation 
1168 m C-C-N str (diazepine ring) 560 w NO2 deformation 
Table 18: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of 
clonazepam61  
7.3.5 Diazepam 
Diazepam is the most basic of the 1,4-benzodiazpines.  There are no additional 
identifying peaks. 
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Figure 41: SERS spectra diazepam 
Wavenumber Assignment Wavenumber Assignment 
1593 vs Arom C=N str (diazepine ring) 1076 m C-C in plane deformation (a, b 
diazepine rings) 
1553 vs Arom C=C str (a-ring) 1023 w C-H in plane deformation (b-ring) 
1423 w Asymmetric CH3 deformation (a-
ring) 
996 m Monosubstituted “breathing” (b-ring) 
1404 m N -CH3 str (diazepine ring) 889 w C-C-N str (diazepine ring) 
1321 s C-H in plane deformation (a-
ring) 
824 w C-N-C str (diazepine ring) 
1275 w C-C in plane deformation (a-
,b,diazpeine ring) 
780 w C-H out of plane deformation 
1207 w C6H5-C vibr. (b-ring) 709 m C-H out of plane deformation (b-ring) 
1168 m C-C-N str (diazepine ring) 689 m C=O deformation 
1144 m CH3 rocking  631 w Ring “breathing” 
1133 w sh C-H in plane deformation (a-
ring) 
593 w C-Cl str 
1111 m C-H in plane deformation (a, 
diazepine rings) 
527 w Out of plane deformation 
Table 19: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of 
diazepam61, 44  
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7.3.6 Flunitrazepam 
Flunitrazepam is a 1,4-benzodiazepine whose spectra can be characterized by the 
very prominent peak at 1344 cm-1 which causes all the other spectral peaks to appear 
weak by comparison.  In addition there is a band at 1568 cm-1 due to the asymmetric NO2 
stretch.   
 
Figure 42: SERS spectra flunitrazepam 
Wavenumber Assignment Wavenumber Assignment 
1594 m Arom C=N str (diazepine ring) 1132 w CH3 deformation 
1568 w Asymmetric NO2 str 1109 w C-H in plane deformation (a,diazepine 
ring) 
1528 w Arom C=C str (a-ring) 1075 w C-C deformation (a,b, diazepine rings) 
1442 w C-H in plane deformation (b-
ring) 
885 w C-C-N str (diazepine ring) 
1344 vs N -CH3 str (diazepine ring) 760 w C-H out of plane deformation 
1168 m C-C-N str (diazepine ring) 670 w C=O deformation 
Table 20: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of 
flunitrazepam44, 61, 86  
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7.3.7 Lorazepam 
Lorazepam is a 1,4-benzodiazpine that has no additional identifying peaks not 
previously discussed.  
 
Figure 43: SERS spectra lorazepam 
Wavenumber Assignment Wavenumber Assignment 
1600 s Arom C=N str (diazepine ring) 1103 m C-H in plane deformation (a, diazepine 
rings)
1558 s Arom C=C str (a-ring) 1029 m Arom C-H str (b-ring) 
1476 s C-H in plane deformation (a-
ring) 
974 w ----------------------- 
1337 vs C-H in plane deformation (b-
ring) 
930 w C-H deformation 
1172 vs C-C-N str (diazepine ring) 856 w C-C-N str (diazepine ring) 
1137 w C-H in plane deformation (a, 
diazepine rings) 
671 w C=O deformation 
Table 21: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of 
lorazepam86, 61, 44  
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7.3.8 Midazolam 
Midazolam is the only 1,2-imidazo-benzodiazpine in this study.  It is also the only 
benzodiazepine with two different halogens on the one molecule, fluorine and chloride.  
There are no additional identifying peaks that have not been previously discussed.  
 
Figure 44: SERS spectra midazolam 
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Wavenumber Assignment Wavenumber Assignment 
1593 vs Arom C=N str (diazepine ring) 1105 w C-H in plane deformation (a, diazepine 
rings)
1562 s Arom C=C str (a-ring) 1033 w C-H in plane deformation (b-ring) 
1503 m Arom C-H str (b-ring) 1013 w Arom C-H str (b-ring) 
1485 w sh Arom C=C str (a-ring) 829 w C-N-C str (diazepine ring) 
1413 m Arom C=C str (a-ring) 732 w ----------------------- 
1305 m Amide III band (N-ring) 689 m Ring “breathing” (N-ring) 
1211 m C-F str (b-ring) 662 w C=C str (a,b rings) 
1166 m C-C-N str (diazepine ring) 634 w ----------------------- 
1137 w Ring “breathing” (N-ring) 590 w C-Cl str (a-ring) 
Table 22: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of 
midazolam85  
7.3.9 Nordiazepam 
Nordiazepam is a 1,4-benzodiazepine that is also the major metabolite of many 
benzodiazepines in this study.  There are no other individual identifying peaks.   
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Figure 45: SERS spectra nordiazepam 
Wavenumber Assignment Wavenumber Assignment 
1599 vs Arom C=N str (diazepine ring) 1027 w C-H in plane deformation (b-ring) 
1555 vs Arom C=C str (a-ring) 993 m Monosubstituted “breathing” (b-ring) 
1479 s C-H in plane deformation (a-
ring) 
946 m ----------------------- 
1336 s C-H in plane deformation (a-
ring) 
869 m C-C-N str (diazepine ring) 
1311 s C-C in plane deformation (a, 
diazepine-rings) 
704 w C-H out of plane deformation (b-ring) 
1260 w C-C in plane deformation (b 
ring) 
686 w Out of plane ring “breathing” 
1230 w CH2 twist (diazepine ring) 671 w C=O deformation 
1204 m C6H5-C vibr. (b-ring) 643 w Out of plane deformation (a,b-ring) 
1167 s C-C-N str (diazepine ring) 587 w C-Cl str 
1136 w C-H in plane deformation (a-
ring) 
525 w Out of plane deformation 
1103 m C-H in plane deformation (a, 
diazepine rings) 
  
Table 23: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of 
nordiazepam44, 61  
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7.3.10 Oxazepam 
Oxazepam is a 1,4-benzodiazpine and is a major metabolite of many 
benzodiazepines in this study.  There are no additional major identifying peaks.  
 
Figure 46: SERS spectra oxazepam 
Wavenumber Assignment Wavenumber Assignment 
1599 s Arom C=N str (diazepine ring) 996 m Monosubstituted “breathing” (b-ring) 
1549 vs Arom C=C str (a-ring) 935 m C-H deformation 
1473 s C-H in plane deformation (a-ring) 856 w C-C-N str (diazepine ring) 
1337 vs C-H in plane deformation (a-ring) 823 w C-N-C str (diazepine ring) 
1172 s C-C-N str (diazepine ring) 749 w C-H deformation (b-ring) 
1133 w C-H in plane deformation (a-ring) 706 w C-H out of plane deformation (b-ring) 
1102 m ----------------------- 520w Out of plane deformation (a,b-ring) 
1021 w C-H in plane deformation (b ring)   
Table 24: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of 
oxazepam61, 44  
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7.3.11 Triazolam 
Triazolam is a 1,2-triazolo-benzodiazpine.  There are no additional major 
identifying peaks.  
 
Figure 47: SERS spectra triazolam 
Wavenumber Assignment Wavenumber Assignment 
1590 vs Arom C=N str (diazepine ring) 1139 w Ring “breathing” (N-ring) 
1563 vs Arom C=C str (a-ring) 1032 w C-H in plane deformation (b-ring) 
1485 s Arom C=C str (a-ring) 1011 w Trigonal ring “breathing” 
1311 m C=N-C sym. str (diazepine ring) 932 w C-H deformation 
1258 w Ring “breathing” (N-ring) 727 m ----------------------- 
1208 w ----------------------- 590 w C-Cl str (a-ring) 
1169 m C-C-N str (diazepine ring)   
Table 25: Observed wavenumbers (cm-1) in the surface enhanced Raman spectra of 
triazolam85  
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8. CONCLUSIONS AND FUTURE WORK 
 This work shows the development of a specific, sensitive, and rapid screening 
technique for the detection of trace levels of benzodiazepines in urine.  The surface 
enhanced Raman spectroscopy method was first optimized looking at a number of 
parameters.  Gold nanoparticle that were approximately 30 nm in size were synthesized 
using a sodium citrate reduction and were found to provide a higher Raman signal 
intensity than three types of silver colloidal solutions synthesized through various 
methods.  This was due to the wavelength of laser available for the thesis providing more 
enhancement for gold than silver at the same wavelength due to the local field intensity 
enhancement factor.  Once the SERS substrate was selected, the concentration and 
aggregating agent was optimized for the detection of eleven different benzodiazepines.  It 
was found that when magnesium chloride at a concentration of 16.7 mM was added to the 
colloidal gold, followed by the addition of drug, the lowest limits of detection (0.5 – 250 
ng/mL) for all eleven benzodiazepines were produced.  All the SERS spectra produced 
were unique to the individual benzodiazepine and were distinguishable.   
This sensitive detection technique was then used in conjunction with a fast clean 
extraction technique, supported liquid extraction.   This technique provided efficient 
extraction of the studied benzodiazepines in fifteen minutes and utilized a sample 
preparation of dilution of urine with an acetate buffer with a pH of five.  This greatly 
reduces sample preparation time when compared to other common sample preparation 
methods such as enzymatic hydrolysis combined with solid phase extraction.  Limits of 
detection of 6-640 ng/mL in urine were determined with the optimized SERS detection.  
This extraction technique was also found to be specific enough to effectively extract the 
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benzodiazepines without coextracting common interference compounds that also 
produced high Raman signals using the optimized SERS method and are found in drug 
facilitated sexual assault victims.  Those benzodiazepines with high limits of detection 
were the tricyclic benzodiazepines.  It can be speculated that the additional ring could be 
contributing to the inefficient extraction by interacting with another compound in the 
urine or inefficiently eluting from the supported liquid extraction sorbent.  These drugs 
also form glucuronides in urine through metabolism and may be reducing the extraction 
efficiency due to the lack of enzymatic hydrolysis in the optimized supported liquid 
extraction.  In order to improve this work, other extraction techniques, that can still 
reduce the time necessary for other current techniques, need to be utilized in order to 
improve the detection limits of the tricyclic benzodiazepines used in this study such as 
alprazolam.  Future work should also examine the cause of this change in efficiency 
between the extraction of the 1,4-benzodiazpines and the tricyclic classes of 
benzodiazepines from urine.   
 In addition, through the interference studies it was found that Δ9-
tetrahydrocannabinol (THC) and codeine provided high intensity SERS spectra using the 
optimized method designed for benzodiazepines.  Future work could be adapted from the 
current method for the sensitive detection of THC and synthetic cannabinoids as well as 
other opiates.  Synthetic cannabinoids are an increasing problem in the forensics 
community and a sensitive detection method that could provide information about their 
identity would prove useful as their structures are constantly being changed creating more 
compounds.  This type of method would allow for the rapid screening for these drugs in a 
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clinical setting where a doctor may not know what is causing a patient’s reaction and 
current immunoassays do not detect for all the synthetic cannabinoids. 
  This method could also be applied to a microfluidic system in the future in order 
to decrease the amount of sample necessary for analysis as well as the time required.  
Microfluidic systems also can be designed to have the advantage of providing sample 
preparation and analysis in one complete system.   The extraction column could be 
embedded in the channel of the microfluidic chip and due to benefit of waste being 
retained by the cartridge and only the analytes of interest being eluted, the analyte could 
then be detected further down the channel without the need for removing the waste.  A 
mixing channel would provide a place to combine the gold nanoparticles, aggregating 
agent, and analyte and detection would be performed through the chip as long as the glass 
used does not produce interferences.   
Overall this combined supported liquid extraction with surface-enhanced Raman 
spectroscopy method has demonstrated a sensitive and selective extraction and detection, 
without interference from common contaminants all in a time of less than twenty 
minutes.  This lowers the time required to process a sample for screening in a drug 
facilitated sexual assault case.  This method also provides spectral information about the 
individual benzodiazepine present though Raman specific peaks allowing preliminary 
identification of the drug though a screening test.   
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APPENDIX A: Use of Raman instrument Perkin Elmer Raman Station 400F using 
Spectrum v.6.35 software 
1.  Turn on in order  
a. Computer 
b. Raman station 400F with the laser 
2. Open Spectrum software 
a. User name Administrator -> OK 
b. Select Instrument (RamanStation 400) 
3. Instrumentation settings/specifications are starts automatically (do not halt) 
a. Resetting beam path motor 
b. Stabilization of laser (60 seconds) 
c. Temperature setting (-50 C) 
4. Once instrument is cooled and stabilized software opens automatically to an 
empty spectrum.  Make sure the sample holder is not in the sampling 
compartment 
5. Select Setup -> Instrument -> Instrument (Figure 48) 
a. Laser Power: 100 % (gives the best spectral views) 
i. Power is 350 mW or 100 mW at sample surface with this setting 
b. Beam path: Sample Compartment 
c. Sample holder: Versatile- Cuvette 
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Figure 48: Instrument setup screen shot 
d. Confirm these accessory configurations.  If the sample holder on the stage 
is different to that selected on the accessory configuration in the 
instrument setting dialog, it may cause severe damage to the instrument 
(jamming the motorized stage and changing the alignment of the stage 
when sample holder is switched.   The Lens Snout (Figure 49) should be 
in the correct orientation for the sample.   
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Figure 49: Picture of proper configuration with sample holder for cuvette analysis 
6.  Select Setup -> Instrument -> Experiment 
a.  Setup (Figure 50) 
i. Set exposure – Keep exposure time between 1 – 5 seconds.  10 
seconds is the maximum exposure however it may lead to 
saturation of the detector 
ii. Set number of exposures – 4  
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Figure 50: Experiment setup screen shot 
b. Advanced (Figure 51) 
i. Spectral information allows for selection of wavenumber range.  It 
is recommended to scan the full range (200 – 3278 cm-1) 
ii. Background handling – Deselect #Backgrounds=#Scans  
iii. Set specific number of background scans to 2 
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Figure 51: Advanced experimental setup screen shot 
7. Select Instrument -> Scan Figure 52 
a. Type out Sample Name Prefix 
b. Select “Archive collected data” and assign location 
i. This will automatically save the scan to the location selected but 
will not automatically open in Spectrum 
ii. If “Send collected data to Spectrum” is selected, the spectrum will 
automatically open following scan however it will not 
automatically save. 
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Figure 52: Scan data collection screen shot 
8.  All scans are automatically saves as *.SP files which can be opened in any 
version of Spectrum software. Other useful file names: 
a. *.SPC – editing files using PE GRAMS software 
b. *.CHR – editing files using Excel software 
9. Instrument should be shut down in the following order 
a. Close Spectrum software 
b. Turn off Raman Station 400F/Laser 
c. Shut down computer 
  
138 
   
APPENDIX B: Standard operating procedure for gold nanoparticle synthesis39, 36  
1. Prepare 10 mL of 1% by weight trisodium citrate in water. 
2. Prepare 100 mL of a 0.5 mM HAuCl4 in water.  Heat solution to boiling under 
reflux with vigorous stirring. 
3. Add 4 mL of 1% tridsodium citrate solution to the boiling 0.5 mM HAuCl4 
solution.   
4. Continue boiling and stirring for 30 minutes. 
5. Remove from heat and allow to cool to room temperature. 
6. Dilute solution to 100 mL following cooling. 
7. Resulting solution should be clear and dark red in color with a UV absorption 
maximum at 522 nm.  
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APPENDIX C: Standard operating procedure for surface enhanced Raman sample 
preparation36  
1. Add 980 µL of prepared colloidal solution to 1 mL sample vile. 
2. Add 10 µL of aggregating agent to colloidal solution, cap and vortex for 30 
seconds. 
3. Add 10 µL of sample to colloidal solution mixed with aggregating agent and 
vortex for 30 seconds. 
4. Samples are allowed to react for 40 minutes prior to running Raman analysis.
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APPENDIX D: Standard operating procedure for supported liquid extraction73  
Extraction using Isolute SLE+ 2 mL extraction columns from Biotage. 
1. Sample Load: 
a. Load 2 mL of pretreated sample on top of column 
b. Pulse vacuum to initiate flow 
c. Leave for 5 minutes to completely adsorb 
2. Sample Elution: 
a. Add 2.5 mL of dichloromethane to top of column 
b. Allow to flow under gravity for 5 minutes 
c. Add additional 2.5 mL of dichloromethane to top of column 
d. Allow to flow under gravity for 5 minutes 
e. Apply short pulse vacuum to elute 
3. Sample Evaporation: 
a. Evaporate sample to dryness 
b. Reconstitute in 100 µL of 10% methanol 
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